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ABSTRACT 
Premature infants have been shown to exhibit fat intolerance with 
the administration of exogenous lipid, especially intravenous lipid. 
Garnitine is required for the efficient oxidation of long-chain fatty 
acids. Since infants have been reported to be unable to synthesize 
carnitine, the carnitine and lipid status was investigated in a series 
of premature infants throughout the entire period of hospitalization. 
At birth, the plasma carnitine of three groups of appropriate for 
gestational (AGA) premature infants (n=36), was compared with full 
term infants (n=lO), and with maternal and umbilical cord plasma 
carnitine levels. The plasma concentrations of carnitine, 
triglyceride, and in some cases free fatty acids, were determined on 
each of the premature infants on days 0-5, 7, and then weekly until 
discharge. The plasma concentration of carnitine and lipid were also 
determined prior to, and after, the initiation of various types of 
infant feedings. The feedings consisted of both carnitine-free and 
carnitine-containi� formula/infusates. The relationship of the 
levels of carnitine and lipid were analyzed between groups to 
determine if lipid intolerance was associated with a depressed 
carnitine concentration. The plasma levels of carnitine and lipid 
were also analyzed to determine their relationship with carnitine, 
fat, and in the case of triglyceride, with calorie intake. 
Results showed. that infant plasma carnitine levels at birth were 
directly related to the maternal plasma carnitine concentration. The 
infant plasma carnitine level was higher in the younger infants when 
V 
compared with the older prematures and full tenn infants. All groups 
exhibited a decrease of the ratio of non-esterified carnitine to 
acid-soluble acylcarnitines soon after birth, which indicated 
metabolism of lipid by B-oxidation. :Most of the infants required an 
exogenous source of carnitine .for the maintenance of the plasma 
carnitine level. H�ver � infants showed a slight elevation of 
plasma carnitine while on a carnitine-free diet. This may have been 
due to either an active biosynthesis of carnitine, a release of 
carnitine from red blood cells, or a release of tissue carnitine. 
All infants res:ponded to dietary carnitine intake with an 
elevation of the plasma carnitine level. The plasma triglyceride 
level was directly related to calorie intake, but correlated to fat 
intake only in the the older premature infants. 
A significant negative relationship between the plasma levels of 
carnitine and triglyceride did not exist in any group. However at the 
time of peak depression of plasma carnitine, the intake of intravenous 
lipid and long-chain fatty acids was relatively lcw. During this time 
most infants received medium-chain triglycerides as the primary source 
of exogenous fat, which might explain this unexpected result. 
Therefore it appears that premature infants tolerate intravenous lipid 
doses of at least 1.0 - 1.5 g/kg/day and diets which contain a high 
percentage of total fat frcm medium-chain triglycerides without 
evidence of fat intolerance even.when they are maintained on a 
carnitine-free diet. 
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CHAPTER I 
INTRODUCTION 
The survival rate among low birthweight (LBW) infants is in­
creasing due to advances in medical understanding and technology. 
Information regarding nutritional requirements and metabolism of 
oxidative substrates in the LBW is limited and vague. Requirements 
for energy and most nutrients are greater than those for term infants, 
since most nutrients are stored during the last trimester of 
pregnancy. However, due to the relative immaturity of metabolic 
systems, the LBW infant has a limited capacity to metabolize 
substrates to meet their higher needs for energy. 
Many LBW infants are fed parenterally for the first few weeks of 
life. Lipid emulsions are ccmoonly used as a source of essential 
fatty acid(s) and calories during the provision of parenteral 
nutrition. Fat is the most calorie-dense substrate, supplying 9.1 
kcal/g. Unfortunately the premature infant does not appear to 
tolerate.moderately large lipid loads. Information regarding the 
exact mechanism for lipid intolerance is unknown at this time. 
carnitine is an essential biocatalyst for the translocation of 
long chain fatty acids into the mitochondria for /9-oxidation. 
Biosynthesis of carnitine in the neonate is thought to be limited due 
to a possible deficiency of r-butyrobetaine hydroxylase, the last 
enzyme in the carnitine biosynthetic pathway. Since carnitine is 
required for the translocation of long-chain fatty acids (LCFA), a 
relative carnitine deficiency may severelv inq;:air the release of 
2 
cellul_ar energy. If carni tine is not present in sufficient amounts, 
this might possibly lead to (1) inability of the infant to gain 
adequate weight, (2) develop hyperlipidemia along with its associated 
toxic effects, and (3) it would ultimately affect the. length of 
hospitalization for the LBW infant. Several investigators have 
studied the relationship between plasma carnitine and plama lipid 
levels. Hc:Mever, long term serial data is not available concerning 
plasma carnitine and lipid levels during an entire hospital stay with 
various nutritional interventions. 
3 
CHAPTER II 
REVIEW OF LITERATURE 
A. Neonatal Metabolism 
In the first three hours of extrauterine life, 90% of the infant's 
glycOQ'en stores are depleted (1). During this time the infant relies 
increasingly on fat as a metab::>lic fuel. The levels of glucagon (2), 
epinephrine and cortisol are increased soon after birth which induce 
lipolysis in adipose tissue (3). Non-esterified fatty acids (NEFA) are 
liberated and oxidized to acetyl CaA which enters the tricarbaxylic 
acid cycle or is used for synthesis of ketone bodies. Both of these 
pathways are useful for spariDJ blood glucose and provide energy for 
adequate tissue :flmction. 
Fat continues to be important energy source during infancy.· 
Premature infants have a higher caloric requirement due to the lower 
digestable energy coefficient and higher fecal energy loss (4), and 
higher energy needs for new tissue synthesis compared with term 
inf�ts (5). Therefore exogenous fat fran formula or parenteral lipid 
emulsion w.JU.ld appear to be a practical means of providing calories to 
the LBW infant. Unfortunately, LBW infants do not tolerate lipid 
well, resulting in an elevation of plasma triglyceride (TG) and/or 
NEFA. The exact cause'of fat intolerance in the LBW infant is unknown. 
4 
B. Review of Lipid Metabolism 
Plasma triglycerides may be derived from dietaiy TG or from 
formation of hepatic ve-ry low density lipoprotein (VLDL). Dietaiy fat 
consists primarily of TG containing long chain fatty acids, although 
some infant formulas are supplemented with medium chain triglycerides 
(MCT) or coconut oil. Long chain triglycerides (LCT) are hydrolyzed in 
the intestinal lumen to m:moglyceride and NEFA prior to absorption. In 
the intestinal mucosa, TG are resynthesized and released into the 
lymphatic system as chylomicrons and later enter the venous system via 
the thoracic duct. During movement from lymph to blood, . chylomicrons 
aqu.ire a:poproteins C and E (Apo-C and Apo-E}. The Apo-C II activates 
endothelial-b:rund li:poprotein lipase (LPL}, catalyzing the hydrolysis 
of TG to NEFA and glycerol. The remaining chylanicron remnant reacts 
with the Apo-E and is taken up by endocytosis into hepatic i;:arenchymal 
cells. 
Medium-chain triglycerides (M:T} are another source of dietary 
fat. Some infant formulas have had a :portion of the LCT removed and 
replaced with M::'I' or coconut oil (59% of the fatty acids are �C:12). 
The K::T are primarily hydrolyzed in the stanach and are absorl:::>ed 
directly into the portal blood system. The� do not require 
emulsification with bile salts, they are not re-esterified in the 
liver, and they do not accumulate in the plasma. 
Plasma TG from endogenously circulating NEFA are synthesized in the 
liver as ve-ry low density lipoproteins (VLDL), which is comprised of 
primarily TG and Apo-B, E, and C. After VLDL release from the liver, 
5 
the VLDL aquires Apo-C II which again activates endothelial-bound LPL 
causing loss of TG and leading to the release of NEFA and glycerol. 
The VLDL remnant may then be modified into lCM density lipoproteins 
(LDL) or after reacting with Apo-E, it may coat, or be engulfed by 
phagocytes. 
Long chain NEFA which are released from TG or adipose tissue are 
transported in the systemic circulation bound to albumin. The 
albumin-bound NEFA are carried to tissues, where they are taken up into 
subcellular organelles for oxidation. The primary site of ,S-oxidation 
is the mitochondria where complete oxidation to acetyl CaA (or to 
propionyl CoA and acetyl CaA ip. odd-chain fatty acid oxidation) is 
accc:mplished. 
Non-esterified fatty acids undergo chain-shortening in the 
mitochondrial matrix which is surrounded by a double membrane. The 
inner mitochondrial membrane is impermeable to fatty acyl-CaA. To 
penetrate, carnitine facilitates intramitochondrial translocation of 
the fatty acid moeity of an acyl-coA with t11e help of carnitine 
acyltransferase A (CAT A), which is located on the outside of the 
inner mitochondrial membrane: 
Fatty acyl-COA + Carnitine __ ..., Fatty acylcarnitine + CaA-SH 
Once inside the membrane, the fatty acyl-cc;:,A is reformed and carnitine 
is released within the mitochondria, a reaction catalyzed by carnitine 
acyltransferase B (CAT B), located on the inside of the inner 
mitochondrial membrane. The activated fatty acid is now available for 
6 
chain�hortening by the enzymes of /3-axidation. 
Unlike long-chain fatty acids, the medium-chain fatty acids are 
not dependent on carnitine for transp:,rt into the mitochondrial for 
their subsequent oxidation. 
Peroxisomes also oxidize fatty acids by a /3-oxidation process. 
Although carnitine palmitoyltransferase is absent in peroxisomes (6), 
Kondrup and LazarcM have shc:N1. that 17-48% of [1-1 4C]palmitate is 
oxidized, or partially oxidized in peraxisanes of rat hepatocytes (7). 
Both the amount and type of dietary fat can affect the rate of hepatic 
peroxisanal and myocardial peroxisanal /3-oxidation activity. Unlike 
mitochondrial-produced acetyl CoA, the peroxisanal acetyl CoA is 
proposed to be committed only to the synthesis of cholesterol. The 
importance of peroxisanal ,S-oxidation in the neonate is unknown. 
C. Fat Intolerance in the Low Birthweight Infant 
Fat intolerance in the LBW infant has been hypothesized to occur 
from decreased oxidation, decreased tissue uptake of NEFA, or from 
decreased plasma clearance of circulating TG (either as chylanicrons or 
VLDL). 
Recently, attention has been focused on fat intolerance secondary 
to administration of intravenous lipid emulsion. Canmercial fat 
emulsions for use in infants are canposed of long-chain triglycerides , 
( 10% w/v), egg yolk phospholipid (as an emulsifier), and glycerol ( to 
obtain an isotonic emulsion). The fat emulsion particles are 
metabolized similarly to naturally-occuring chylomicrons (8). The fat 
emulsion is suitable for peripheral or central infusion, and it may be 
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administered as a bolus (slowly) or continuously throughout a 24 hour 
period. 
Fat intolerance as a result of intravenous lipid administration 
may occur at various fat doses (9, 10, 11, 12). Griffin (9) found that 
when either bolus or continuous infusion of fat emulsion was 
administered, plasma TG levels would peak and. plateau within 5 hours 
after the initiation of the fat emulsion. The TG plateau was 
. maintained throughout the period of infusion, however there were wide 
day to day variations in the plateau levels acheived in the individual 
infants. These variations could not be explained by either mode of 
infusion or lipid dose'. 
Hilliard et al. (10) found that AGA premature infants (26-32 weeks 
at birth) had increased plasma concentrations of TG, NEFA, total lipid, 
and glycerol when at least 2 g/kg/day or more of lipid was given by 
continuous infusion. There was no further significant increase in 
plasma lipids until roore than 4 g/kg/day was administered. In the same 
study, NEFA concentration remained within baseline, pre-infusion range 
(0.41 ± 0. 046 mnol/dl) with infusions of up to 2 g/kg/day of lipid. 
Infusion of 3-4 g/kg/day of lipid produced very wide variations in NEFA 
concentration, with mean levels significantly greater than baseline 
(1.2 l1111¥)1/dl) at 96 hours, but the NEFA level was not significantly 
greater than when the,lipid dose was 2 gm/kg/day. 
Hilliard found that plasma TG levels were significant above 
pre-infusion levels (but not in an abnormal range) when a lipid dose of 
1 g/kg/day was administered. Preinfusion TG concentration averaged 
0.30 ± 0. 031 nmol/dl and at 4 hours after the start of lipid infusion, 
8 
plasma TG were significantly higher than baseline levels when the 
lipid dose was 1 g/kg/day. Unlike the results of Griffin, a TG 
plateau was not maintained throughout the period of lipid infusion. 
At 8 and 12 hours after the start of lipid infusion, TG had decreased 
to the upper statistical limit of pre-infusion levels. As the dose 
was increased above 1 g/kg/day on a daily basis to the maxinrun dose of 
4 g/kg/day, only one 23 week infant obtained a TG level of 2.5 
mrool/dl. Thus, it appears that IIK)St infants can be given up to 4 
g/kg/day of intravenous lipid without evidenc;:e of hypertriglyceridemia 
as long as the lipid is administered as a continous, rather than 
bolus, infusion. 
Cooke et al. (11) recently investigated the lipemic effects of 
giving bolus infusions of safflower oil-based lipid emulsion (Liposyn, 
Abbott Labs). Two similar groups of preterm infants (28-34 weeks) were 
infused with lipid, with doses either 0. 34 g/kg/day or 0. 68 g/kg/day 
for 5 days. There was a higher indicence of hypertriglyceridemia 
(defined as >200 ng/dl) in the group receiving the higher lipid dose 
(9 of 16 versus 2 of 8 in the 0.34 g/kg/day group). However there was 
no difference in NEFA l�ls between the groups despite the difference 
in lipid dose. Cooke noted that in infants :s32 weeks, the post­
infusion NEFA were greater (NEE'A uptake was less) than infants 32-34 
weeks gestation. 
Andrew et al. (12) observed that although lipid tolerance was 
related to gestational age, it was also related to weight for 
gestational age. These infants were given bolus infusions of soybean 
oil-based lipid emulsion (Intralipid), at a dose of 1 g/kg/day over a 4 
9 
hour period. Infants s33 weeks gestation and the small for gestational 
age (SGA} infants of 32-40 weeks gestation had significantly higher 
concentrations of TG and NEFA during the infusion period and they 
cleared the lipid more slowly than the AGA infants >33 weeks 
gestation. 
These studies suggest lx>th impaired hydrolysis of the infused 
lipid and inefficient uptake and/or utilization of lipid in the 
premature infant. '!hey also.suggest that intravenous fat is better 
tolerated when administered as a continuous infusion. 
D. canplications of Lipid Intolerance 
The infusion of lipid emulsions have been associated with 
canplications in LBW, premature infants. Hypertriglyceridemia due to 
lipid infusion has been reported to be associated with hypoxia (13} and 
exacerbation of existing ventilation/perfusion inequalities (14) which 
are frequent in premature infants. Lipid emulsion administration has 
been proposed to inhibit neutrophil function ( 15, 16) , and canpromise 
inmunfty against bacterial infection ( 17) • Therefore caution is taken 
to avoid large lipid doses, especially in the premature infant. 
An increase of plasma NEFA has also been associated with adverse 
effects. Plasma NEFA in excess of a NEFA to albumin molar ratio of 6:1 
can competitively displace bilirubin fran its primary binding site (18). 
This would increase the level of free bilirubin in the blood of infants 
who are already at an increased risk of developing kernicterus. Kao et 
al. (19) compared the NEFA:albumin molar ratio of infants of either 
28-32 weeks or >32 weeks of age during either a continuous or lx>lus 
10 
lipid infusion. With continuous infusion in infants �32 weeks 
gestational age, the NEFA/albumin molar ratio remained constant only 
when the lipid dose was <l g/kg/day. The molar ratio exceeded 10:1 as 
the lipid dose approached 2 g/kg/day. At a lipid dose of 2. 5-3. O 
g/kg/day, the ratio increased to 10-14:1. In infants >32 weeks the 
molar ratio did not approach 6:1 until administration of approximately 
2.5-3.0 g/kg/day of lipid. The older infants never attained the higher 
NEFA:albumin molar ratios (10-14:1) of the infants �32 weeks of age. 
All infants tolerated the intermittent regimes (daily lipid 
administration for 8 hours) less than when the intravenous lipid was 
given continuously. With intermittent lipid infusion, the peak ratio 
was >6:1 in all infants �32 weeks at any lipid dose, and they acheived 
a ratio of 24:1 at lipid intakes of 2.5 g/kg/day. In infants >32 
weeks, lipid doses up to 2 g/kg/day did not adversely affect the 
NEFA:albumin ratio. Hat.ever, when the lipid dose was increased to 5 
gm/kg/day, the molar ratio exceeded 12:1. As with the continuous 
administration of lipid, infants >32 weeks never attained the molar 
ratio seen in the more innnature infants. 
E. Etiology of Lipid Intolerance 
It would appear that fat intolerance in the LBW infant is 
multifactorial and·the proposed etiologies are quite m.nnerous. Plasma 
NEFA may be elevated by the presence of stress-related hormones, a 
compranised nutritional state (a high glucagon to insulin ratio), or 
during administration of drugs such as theophylline and dopamine (20) 
which may initiate and/or potentiate lipolysis in the newborn. 
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Cellular uptake of NEFA may be poor in premature infants due to 
relatively low numbers of adipocytes (21). An inadequate source of 
a-glycerol phosphate (22) due to depleted glycogen stores may prevent 
NEFA re-esterification with subsequent NEFA accumulation in the blocxi. 
Depressed plasma carnitine has also been correlated with elevated 
levels of plasma NEFA (23,24) duriDJ the parenteral infusion of fat 
emulsion. 
Hypertriglyceridemia may result fran decreased activity of certain 
enzyme systems or fran the accumulation of endogenously produced or 
exogenously provided lipid or carbohydrate. Lipoprotein lipase (LPL) 
activity is age-dependent; infants< 27 weeks have one-third of the 
reserves of LPL of term infants (25). The LPL activity parallels 
calorie intake ( 26) , haviDJ a very low activity when intake is low and 
increasing accordiDJly (27). In animal studies, both viral and 
bacterial infections have been sham to depress LPL activity (28), 
leadiDJ to elevated plasma triglyceride. Glucose provided to pre­
matures in excess of what can be directly oxidized for energy, 
7 ng/kg/min ( 29) , must first be converted into lipid before oxidized 
for energy. Lecithin-cholesterol acyltransferase was recently found 
to be deficient in premature infants (30), a condition which could 
indirectly elevate plasma triglyceride concentration. Cooke et al. 
(31) reported that hypertriglyceridemia is more conunon in infants 
receiving a safflower oil-based lipid emulsion (Liposyn), when 
compared to a similar group of infants being infused with a soybean 
oil-based emulsion (Intralipid). 
On the other hand, administration of tvK::T preparations have been 
12 
shown to have beneficial results in the neonatal rat (32,33). The 
medium-chain fatty acids have been shown to support ketogenesis and 
prevent hypoglycemia in the newborn rat. These effects are attributed 
to the faster rate of hydrolysis and oxidation of MCT compared to 
long-chain fatty acids. Unfortunately, there are currently no MCT 
preparations suitable for intravenous use. 
F. carnitine Metabolism 
As mentioned previously carnitine (CNE), 3-hydroxy-4-N-trimethyl­
aminobutyric acid, is absolutely required for the intramitochondrial 
translocation of long chain fatty acids. Lack of camitine may lead to 
a relative inability of tissues to oxidize lipids for energy. 
Carnitine may also be linked to energy release through other less 
elucidated pathways. Carnitine has been proposed to be a stimulator of 
lipolysis in subcutaneous adipose tissue and a recoupler of oxidative 
phosphorylation in brown adipose tissue of newborns ( 34) . carni tine 
may play a facilitative role to stimulate the decarboxylation of 
branched-chain amino acids (primarily leu.cine) in skeletal muscle 
tissue. This is accomplished by increasing the rate of conversion of 
the branched chain ketoanalogs into camitine esters for entry into the 
mitochondria (35). The CoA-SH pool is regenerated, allcming the 
branched-chain ketoacid dehydrogenase reaction to shift to the right 
and stimulate further branched-chain amino acid oxidation in order to 
support gluconeogensis. Carnitine may also function as a transport 
vehicle for acetyl and medium-chain acyl residues out of peroxisomes, or 
for transport of the products of peroxisanal /3-axidation to the 
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mitochondria or the endoplasmic reticulum (6). 
carnitine availability in the mitochondria could theoretically 
regulate the oxidative metabolism of carbohydrate, glucogenic amino 
acids as well as lipid (6). By converting acyl-CaA's into 
acylcarnitines, there is regeneration of the CoA-SH pool in the 
mitochondrial matrix. Coenzyme-A is then available for the production 
of acetyl CoA ( from pyruvate) , succinyl CaA ( fran a-ketogluterate) , 
branched chain acyl CaA (fran branched-chain keto acids) and long chain 
fatty acyl CoA ( from long chain NEFA). All of these are important for 
· release of metabolic energy. 
G. Sources of Carnitine 
carnitine may be obtained fran endogenous biosynthesis, dietary 
intake, and in the newb::>m, fran placental transfer. carnitine is 
synthesized fran protein-bound lysine, methionine, and requires the 
cofactors ascorbic acid, niacin, pyridoxine and ferrous iron (37). In 
humans, r-butyrobetaine hydraxylase, the limiting enzyme in the 
conversion of r-butyrobetaine to carnitine was found to be only 12% of 
adult levels in infancy ( 37) . Decreased activity of this enzyme may 
indicate that carnitine is an essential nutrient during infancy. 
Cofactors necessazy for carnitine biosynthesis may be present in 
deficient amounts in the LBW and may contribute to the infants in­
ability to synthesis carnitine. Cord levels of pyridoxine are lower 
in premature infants than in tenn infants (38). Infants on total 
parenteral nutrition have deficient plasma levels of pyridoxine (39). 
Rats given the B-6 antagonist, 1-amino-D-proline, show a 60-80% 
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depression of carnitine production frcm trimethyllysine (40). Also, 
LBW infants have reduced iron stores at birth (41). It was shown that 
iron depleted rat pups had 42% lower liver carnitine levels and an 
8-fold increase in triglyceride concentration, even when adequate 
lysine and methionine were provided in the diet (42). Premature 
infants deficient in any of these precursors or cofactors may have 
reduced concentrations of carnitine. 
Dietary sources of carnitine include meat and milk products. 
Milk-based commercial infant formula and human breastmilk are good 
sources of carnitine. Human breastmilk averaged 75 nmol/ml when 
measured by Ohtani ( 43) • Ccmnercial milk-based infant formulas 
contained significant, but variable amounts of carnitine. Commercial 
infant formula based ori soy, casein and egg white proteins contain only 
minute quantities of carnitine (44). Intravenous amino acid solutions 
and lipid emulsions are virtually carnitine-free, <1 nmol/ml (45). 
In the fetus, carnitine is obtained by placental transfer from the 
maternal blood supply. Placental transfer of carnitine has recently 
been elucidated in humans. Using an in vitro, double circuit perfusion 
design, Schmidt-Samnerfeld et al. (46), concluded that (1) placental 
carnitine transfer occurs by passive diffusion through extracellular 
channels, (2) there is stereospecific cellular uptake for the L-isomer, 
although both the D- and L-isaners diffuse into the placenta similarly, 
and (3) the human placenta is actively involved in carnitine metabolism, 
having the ability to esterify free carnitine. The authors also 
concluded that, based on their calculated maximal transfer of 500 
µrool/day and a 13 µrool/day carnitine accumulation during the last 
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trimester into the fetus (47), carnitine delivery to the fetal 
circulation is in excess of fetal requirements and fetal biosynthesis 
�d probably not be necessary. 
H. carnitine Acyltransferases 
Carnitine is the substrate for various carnitine acyltransferases. 
These enzymes are essential for acylcarnitine transport through various 
membranes. Of special importance in lipid oxidation is carnitine 
palmitoyltransferase (CPT). This enzyme is responsible for activated 
palmitic acid entry into the mitochondria. The CPT activity is 
exclusively located in the mitochondria of liver, heart, kidney and 
skeletal muscle (48). In term newborn infants, there is a significant 
increase of CPT activity in white adipose tissue mitochondria of term 
infants 20 hours old when canpared with the CPI' activity at 0-10 hours 
of age in the same infants. The CPI' activity was l�r in prematures 
when compared with the term infants during the entire 20 hours (49). 
In newborn rats, CPI' levels are low but increase with time. Adult 
levels of CPT are obtained in liver by 4 days, but not in skeletal 
muscle until 15 days of life (44). Earlier activity of hepatic CPI' 
probably reflects the importance of ketogensis in the newborn. 
Carnitine palmitoyltransferase is proposed to be inhibited by 
malonyl CoA (51) and intramitochoridrial myocardial pyruvate (52), and 
activated by palmitoyl CoA (53). 
The short and meduim chain acyltransferases, substrates mentioned 
previously, are located in mitochondria, peroxisomes and endoplasmic 
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reticulum. Their primary function is thought to be protection of the 
CoA-SH pool and for membrane transport function (6). 
I. Plasma carnitine 
1. Factors Affecting Plasma Carnitine Concentration 
The plasma carnitine concentration in humans varies with age, sex, 
endocrine and nutritional status, and disease. The plasma carnitine 
level required for normal metabolism is not known, since the 
relationship of tissue and plasma carnitine levels may not be cor­
related ( 54) . Normal, heal thy men have been reported to have plasma 
values of 57.3 ± 12. 8 nmol/ml (mean ± 1 SD}, and non-pregnant fertile 
women of 46. 5 ± 12. 4 nmol/ml (55). It has been shown that rats 
injected with androgens have an increased plasma carnitine level, and 
rats injected with estrogens will have a decreased plasma carnitine 
level (56), which may explain the sex differences of carnitine in 
human adults. Infant plasma carnitine levels are similar between 
males and females (57). Diet may also affect the level of plasma 
carnitine. Chronic starvation (58) is also associated with a decrease 
in plasma carnitine levels in humans. In guinea pigs, a diet 
deficient in ascorbic acid reduced the muscle carnitine concentration 
(58) and in newborn rats, a diet deficient in iron decreased the 
plasma carni tine concentration ( 43) . 
2. Garnitine Deficiency 
Carnitine deficiency has been proposed as an etiology of 
endocardial fibroelastosis in infants and children (59), and in some 
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cases of dilated cardiomyopathies (60) , lipid storage diseases (61, 62) , 
and non-ketotic hypoglycemia (63, 64) because of defects in /3-oxidation. 
Depressed levels of plasma carnitine are seen in Fanconi Syndrome due 
to insufficient reabsorption of carnitine (65) , and in chronic renal 
dialysis patients due to loss of carnitine into the dialysate (66, 67) . 
3. Carni tine in Pregnancy · 
Pregnant women have lower plasma carnitine concentrations [17.40 ± 
1.23 ruool/ml (68) , and 17.95 ± 1.00 nmol/ml (69) ] compared with 
non-pregnant women (46.5 ± 12.4 nJOOl/ml (55) ]. ·Hypertensive pregnant 
females have slightly higher levels of total carnitine. Pregnant 
diabetics have similar total carnitine levels than non-diabetics, 
however they have significantly lower concentrations of acylcarnitine. 
In all pregnant women, the concentration of plasma carnitine tends to 
decrease with advancing gestation, with lowest concentrations reported 
in mothers giving birth to term infants (69) . 
4. Infant Carnitine 
Umbilical cord and infant plasma concentrations of carnitine are 
directly related to maternal levels of carnitine (68) . The plasma 
carnitine level is higher in premature than in term neonates, 29.0 ± 
1. a (mean ± SEM) versus 22. 4 ± 0 .  8 rm:>l/ml (p<O. 001) (_57) . The mean 
plasma carnitine value in the unfed neonate is unchanged at 4 hours of 
age ( 68) . However, plasma ca.mi tine concentrations rapidly decrease in 
premature newb:>rns during the first 3 days after birth if no exogenous 
carni tine is given ( 70) . 
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J. Tissue carnitine 
Skeletal muscle tissue carnitine concentrations, unlike plasma 
levels, are lower in preterm compared to term infants (71, 72) and 
adults (71) . There is a positive relationship between muscle 
carnitine and gestational age (r=0.832, p<0.001) and birthweight 
(r=0.746, p<0.001) . However, no correlation was found between 
gestational age or weight with liver and heart carnitine 
concentrations (71) . Up:m initiation of feedings, tissue carnitine 
levels increase in infants given a carnitine-containing formula or 
intravenous carnitine supplement. Infants maintained on parenteral 
alimentation for more than 10 days had laer heart, liver and kidney 
carnitine concentrations than controls (infants who died before 24 
hours after birth) ( 72) . Shenai and Borum ( 71) concluded that the 
inverse proportion of plasma and tissue carnitine levels at birth 
probably reflect enhanced placental acquisition or decreased tissue 
uptake of carnitine in the premature infant. They concluded from this 
obse�tion that the premature infant is at greater risk for 
developing carnitine deficiency in the postnatal period. 
K. Relationship of Plasma carnitine.to Diet 
As mentioned, the infant plasma carnitine level depends on an 
exogenous source of carnitine. In infants, all fractions of carnitine 
decrease on a virtually carnitine-free diet and increase when carnitine 
is present in the diet (73) . In weanling rats, dietaxy manipulation 
will change the ratio of non-esterified carnitine to acylcarnitine 
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(NEC :ASAC ratio) , without changing the concentration of total plasma 
carnitine. Starvation or diets high in medium chain triglycerides or 
total fat will decrease the NEC :ASAC ratio (74). In older premature 
infants, administration of parenteral lipid emulsion caused an increase 
in acylcarnitine while total ca.mi tine was maintained (75). However 
Yeh et al. (76)_ found that in younger premature infants there was a 
small insignificant increase in acylcarnitine during administration of 
fat emulsion. The premature infants exhibited lower ASAC levels than 
the term infants during a 5-9 day course of parenteral nutrition. The 
levels of J3-hydroxybutyrate were found to be lower, while NEFA were 
significantly higher in the premature infants maintained on a total 
parenteral nutrition regime (which included lipid emulsion) when 
canpared to term infants. 
L. Relationship of Plasma Garntitine and Lipid Concentrations 
Schmidt-Samnerfeld et al .  (75) re:r;x:,rted a positive relationship 
between total carnitine and J3-hydroxybutyrate and between acylcarnitine 
and J3-hydroxybutyrate (r=0. 45, p<0.05, and r=0. 79, p<0.001 , 
respectively). Also , there was a negative relationship between plasma 
levels of total carnitine and NEFA (r=-0.47, p<0. 025 ) (57), and between 
non-esterified carnitine and NEFA levels (r=-Q.653, p<0.01)(24). From 
these results , both Yeh and Schmidt-Sanmerfeld attributed carnitine 
insufficiency to the inability of the premature infant to adequately 
metabolize the parenteral lipid as an energy source. 
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M. carnitine Supplementation 
Intravenous carnitine supplementation produces a rapid rise in 
plasma free carnitine (77) . 'lw:) hours after a 100 ng/kg dose of 
L-carnitine in neonates, plasma free carnitine increased to 
1108.1 ± 132.2 nmol/ml. Acylcarnitines were also increased, showing 
that the infused carnitine is acylated in the neonatal tissues. 
However in the same study, _there was no difference in lipid tolerance 
when a l g/kg dose of lipid emulsion was administered simultaneously 
with the carnitine supplement. 
The effectiveness of intravenous carnitine supplementation to 
pranote adequate fat metabolism has not been determined. The few 
studies which have been done in infants utilized only short term doses 
of supplemental carnitine. Orazali et al. (78 )  administered 
intravenous D,L-carnitine at an initial dose of 100 ng/kg foll� by 
a continuous dose of 100 ng/kg over 6 hours with a similtaneous low 
dose (1 g/kg) of intravenous lipid emulsion. The subjects were older 
premature infants, having a mean gestational age of 36 weeks . After 
carnitine administration, the plasma ketone, NEFA and glycerol 
concentrations were all elevated when canpared to the controls who did 
not receive carnitine supplementation. Triglyceride levels were not 
different between the groups during or after the infusion period. 
However, considering the older gestational age of the infants, the 
small lipid dose administered, and the short. term administration of 
the carnitine supplement, no firm conclusions can be applied to the 
very low birthweight infant. 
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Studies are not available relating long term intravenous (or oral) 
carnitine therapy and lipid tolerance in infants. Investigators have 
shown that adults with Type IV hyperlipoproteinemia and adults and 
children on chronic hemodialysis have lower serum triglyceride levels 
when placed on long term oral carnitine supplementation (79, 80, 81, 82). 
Several of the reported cases of systemic carnitine deficiency have 
also responded to carnitine supplementation (61, 62). 
Since premature infants appear to be at risk for developing both 
fat intolerance and carnitine deficiency, a relationship may exist 
between plasma levels of fat and carnitine. 
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CHAPTER III 
EXPERIMENTAL PROCEDURE 
This study included 46 appropriate for gestational age (AGA) 
infants born in, or admitted to, the Department of Pediatrics at the 
University of Tennessee Memorial Research Center and Hospital. The 
study was approved by the University of Tennessee Center for Health 
Sciences Institutional Review Board for Human Studies. Informed 
consent was required from a parent (or guardian) before an infant was 
included into the study. The subjects were classified into one of 
four groups based on birthweight. The four groups were : Group I, 
<1000 g ;  Group II, 100�-1510 g ;  and, Group III, 1511-2500 g ;  and 
Group r.v, term AGA infants which served as the reference group for 
birth values. In the study, the infant birthweight ranged from 570 to 
4536 g and the gestational age ranged from 24 to 42 weeks (Table 1 ) .  
Infant diets were ordered at the discretion of the attending staff 
physicians. Diets included both carnitine-free (<1 nmol carnitine/ml) 
and carnitine-containing formula/infusates . Carnitine-free diets 
consisted of total parenteral nutrition (TPN) which contained dextrose 
(varying concentrations) and crystalline amino acids, Aminosyn (Abbott 
Labs, North Chicago, Il. ) , intravenous lipid emulsion (Liposyn, Abbott 
Labs ) ,  and a conmercial soy protein-based formula, Portagen (Mead 
Johnson Labs ) .  carnitine-containing diets included Enfamil-20 (20 
kcal/oz ) ,  Enfamil-Premature Formula (Mead Johnson Labs ) , and breastmilk. 
The infants were placed on any number of these diets during 
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hospitalization. There was no particular order in which any infant or 
group received a particular type of diet. 
Table 1. Weight and Gestational Age of Infants at Birth 
Group n Weight (g) Gestational Age 
(weeks) 
I 10 780 ± 43.721 26.5 ± 0.53 
II 10 1350 ± 44 . 64 31.1 ± 0.53 
III 16 1903 ± 61.45 33.1 ± 0.38 
10 3391 ± 184.54 39.8 ± 0.49 
l Mean ±  SEM 
Blood samples (approximately 1 ml ) were obtained for carnitine and 
lipid analysis fran the mother within 16 hours after delivery and fran 
umbilical cord within 4 hours after delivery. An sample of blood for 
routine hospital testing was also obtained from each infant soon after 
birth. SUbjects in Groups I-III had daily blood samples drawn on days 
0 , 1 , 2 , 3 , 4 , 5  and 7 of life , and then only prior to and after nutritional 
intervention , or weekly until discharge. All blood was collected in 
heparinized test tubes and centrifuged .immediately at 4°. Plasma was 
separated and frozen at -20° until analyzed . 
Plasma triglyceride and carnitine (non-esterified carnitine , acid­
soluble acylcarnitine , and acid-insoluble acylcarnitine) levels were 
detennined for each sample . Non-esterified fatty acid levels were 
measured on a portion of the samples obtained f�om Group I infants. 
Samples obtained following whole blood transfusions were excluded from 
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statistical analysis. 
A. Plasma Triglyceride Determination 
Plasma triglyceride ( TG )  was determined on each sample using the 
procedure of Giegel (83). The TG assay is based on the principle that 
plasma lipids may be extracted with nonane. The extracted TG are 
transesterified to yield three ethyl esters (soaps of fatty acids) and 
glycerol. The resulting glycerol is then oxidized to fonnaldehyde by 
periodate. Condensation of fonnaldehyde with ammonium ion and 2, 4-
pentadione will produce. 3,5-diacetyl-1,3-dihydrolutidine which is a 
colored canpourxi and can be measured spectrophotanetrically at 415 nm. 
The method was modified to accomodate a 50 µl plasma sample size. 
When tested, the modified technique resulted in 101. 8% recovery 
compared to the standard technique described by Giegel. 
1. Reagents 
1. Extraction reagent : n-nonane (Fisher Scientific, Fairlawn, 
NJ) was mixed with isopropanol to obtain a 2. 0/3 . 5  (v/v%) mixture. 
2. Triolein standard ( lOOmg/dl) : 5. 4 ng triolein (Sigma Chemical 
Co .  , St. Louis, MO) was added to 5 . 4 ml of extraction reagent ( #1 ) , 
mixed, and stored at -20°. 
3. SUlfuric acid ( 40 rrN H2so 4) : O. 221 ml of concentrated H2so 4 
was added to . 100 ml of glass distilled water and the volume was 
brought to 500 ml with glass distilled water. 
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4 .  Transesterifying reagent : sodium hydroxide ( 100 mM) in 
isopropanol : 0 . 40 g NaOH was dissolved in approximately . SO ml of 
isopropanol and was brought to volume with isopropanol in a 100 ml 
volumetric flask . 
5. Acetic acid (2 M CH
3co2H ) : 22.88 ml of glacial acetic acid 
was added to approximately 150 ml of glass distilled water and the 
volume was brought to 200 ml with glass distilled water. 
6. Oxidizing reagent : sodium periodate ( 18 mM) in acetic acid : 
0 . 3850 g sodium periodate was dissolved in approximately 80 ml of 2 M 
CH
3
co
2
H (#5 ) ,  mixed, and the volume was brought to 100 ml with 2M 
CH
3
C0
2
H. 
7. Color buffer : amnonium acetate ( 6M CH
3
CooNH4 ) : 462. 48 g 
CH3COONH4 
was dissolved in approximately 700 ml of glass distilled 
water. The pH was adjusted to 6.0 with glacial acetic acid , and the 
volume was brought to 1 liter with glass distilled water . 
8. Acetylacetone (2 , 4-pentadione) : reagent grade , (Fisher 
Scientific, Fairlawn, NJ ) .  
9. Color reagent : acetylacetone in color buffer : 4 ml of 
acetylacetone (#8 ) was added to each 100 ml of color buffer (#7) and 
mixed vigorously and allowed to stand at least 15 minutes before use. 
This solution is stable for 8 hours at room temperature and was made 
fresh before each assay. 
2 . Procedure 
Extraction of triglyceride was accanplished by adding triolein 
standard (0 , 0.02 , 0 . 05 ,  0.1 , 0.2 and 0.3 ml) to 100 x 75 JlUil glass test 
26 
tubes containing extraction reagent { 2. 50, 2. 48, 2. 45, 2. 40, 2.30 and 
2.20 ml, respectively), 0.1 ml glass distilled water and 0 . 5  ml H2so4 . 
Sample unknowns were prepared by adding 0.05 ml plasma to 2.45 ml 
extraction reagent, 0.1 ml glass distilled water and 0.5 ml H2so4. All 
standard and sample tubes were vortexed and centrifuged at 4 ° for 10 
minutes at 1500 x g, using a Beckman centrifuge (Beckman Instruments, 
Palo Al to, CA) . A O. 25 ml portion of the upper nonane phase was 
obtained from standard tubes and b«> 0. 25 ml portions were obtained 
fran unknown tubes. A volume of 25 ml of transesterifying reagent was 
added, tubes vortexed and allowed to stand at least 5 minutes at room 
temperature. At this time 0. 25 ml of oxidizing reagent was added to 
each tube ,  tubes were vortexed, am then allowed to stand at room 
temperature for at least 2 minutes, at which time 3. 0 ml of working 
color reagent were added to each tube .  All tubes were then capped, 
vortexed, and placed in a 56-60 ° water tath for 10 minutes to allow 
developnent of color. Once removed, the tubes were cooled to room 
temperature and absorbance was determined in a spectrophotaneter 
{Beckman M:xiel 34, Beckman Instruments, Fullerton, CA) at 415 nm. The 
concentration of known standards was plotted against absorbance and a 
standard curve was constructed. The inverse slope of the standard 
curve was estimated from the standard plot. 
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Triglyceride concentration of the unknowns was detennined as 
follows: 
Triglyceride (ng/ml) = A (unknown) * IS *  df 
where : A = absorbance at 415 run, 
IS = inverse slope of the standard 
curve, and 
df = dil.ution factor ( = 1000) . 
B. Plasma carnitine Determination 
Plasma carnitine concentration was determined by the radioisotopic 
procedure of Cederblad and Lindstedt ( 84), and as mcxiified by others 
( 85). The assay is based on the principle that non-esterified (free) 
L-carnitine will react with [1- 1 4C]acetyl CoA in the presence of 
carnitine acetyltransferase with subsequent formation of 
[ 1- 1 4C]acetylcarnitine. Placement of the mixture on anion exchange 
resin will exchange chloride ions for excess CoA. Therefore the eluate 
contains only labelled acetylcarnitine, which is evaluated in a liquid 
scintillation counter. 
The standard assay used regularly in our lab utilizing a 100 µl 
sample size was modified to accanodate a 50 µl sample volume. When 
tested, the modified technique resulted in 95. 4% recovery compared to 
the standard assay. 
1. Reagents 
la. Carnitine Standard Solution ( 0. 5  mM) : 0. 988 g of L-carnitine 
HCl ( Sigma Chemical Co. , St. Louis, MO} was dissolved in cold glass 
distilled water and the total volume was brought to 100 ml with glass 
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distilled water in a volumetric flask. One ml portions were dispensed 
into plastic tubes and frozen a -70°. Fach portion was diluted 
appropriately (0.25 mM) for the working standard solution. 
lb. Palmityl Carnitine Standard (22.9 mM) : 1.0 ml of glass 
distilled water was added to a vial containing 10 ml of L-palmityl 
carnitine (Sigma Chemical Co. , St. Louis, MO) . This was diluted 
appropriately (0.229 mM) for the working standard solution. 
le. Carnitine Standard Mixed Solution: 1. 0 ml of 0. 25 mM 
L-carnitine HCl was added to 1.0 ml of 0. 229 mM L-palmitylcarnitine, 
mixed, and stored frozen at -20°. 
2. Potassium Hydroxide (0. 5 N KOH) : 28.055 g KOH pellets were 
dissolved in glass distilled water and the total volume was brought to 
1 liter with glass distilled water. 
3. Perchloric Acid ( O. 6M) : 51. 26 ml of 70% Perchloric acid was 
added to 500 ml of glass distilled water and the total volume was 
brought to 1 liter with glass distilled water. 
4. Sodium Tetrathionate (0. 1 mM Na
2
s
4
o
6
) :  O. 7656 g of Na2s4
o
6 
was dissolved in glass distilled water and made to volume in a 25 ml 
volumetric flask. 
5. Phenol Red ( o. 1%) : O. 1 g of Phenol Red was dissolved in 100 
ml of absolute ethanol. (Phenol Red tubes were made by adding one drop 
of Phenol Red indicator to 12 x 75 nnn Pyrex glass tubes and allowed to 
dry) . 
6 .  Radioactive Acetyl Coenzyme A (50 mCi/mM) : 50 µCi of 
( 1- 1 4C]acetyl coenzyme A (Amersham Corp. , Chicago, IL) was dissolved in 
300 ml of cold glass distilled water. Portions of approximately 9 ml 
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were dispensed into plastic vials and frozen at -60 °. 
7 .  Potassitnn Bicarbonate ( 1 M KHC03) : 1. O g of KHC03 was 
dissolved in glass distilled water and the total volume was brought up 
to 10 ml in a graduated conical test tube. 
8. Acetic Anhydride [ 0. 1  M (CH3co)20] : 0. 5 ml of (CH3co)2o was 
added to 4. 95 ml of cold glass distilled water, mixed, and used 
immediately for the acetyl CoA solution. 
9. Acetyl Coenzyme A (0. 1 mM) : 10 ng of coenzyme A (Sigma 
Chemical Co. , St. Louis, MO )  was dissolved in 0. 5 ml of cold glass 
distilled water. To this, 100 µl of 1 M KHC03 was added. Then, 200 µl 
of 0. 1 M acetic anhydride was added and the volume was brought to 80 ml 
with cold glass distilled water. After mixing, the solution was 
dispensed into plastic tubes in approximately 8 ml :portions and stored 
at -60 °. 
10. carnitine Acetyltransferase (Pigeon Breast Muscle) : acetyl 
CoA : carnitine-0-acetyltransferase (Sigma Chemical Co. , St. Louis, MO) 
was diluted with glass distilled water to 50 units/ml, gently mixed, 
then refrigerated in approximately 1 ml :portions until use. 
11. MJPS Buffer ( 1 M [ 3-{ 4-morpholino }propanosulfonic acid ])  : 
20. 92 g of MOPS (Sigma Chemical · Co. , St. Louis, IvD) was dissolved in 
approximately 80 ml of glass distilled water. The pH was adjusted to 
7 . 4  with 4 N KOH, and ,the volume was brought up to 100 ml with glass 
distilled water. 
12. PCA/MOPS I :  20. 9 g of K>PS was added to 20 ml of O. 6 M 
perchloric acid and brought to 100 ml with glass distilled water. 
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13. PCA/MOPS II: 20. 9 g of MOPS was added to 20 ml of 0. 6 M 
perchloric and and brought to 100 ml with glass distilled water. 
14. EGTA (0. 1 M, pH 7. 0) : 1. 902 g of EGTA 
[Ethyleneglycol-bis (B-amino-ethylether)N, N ' -tetraacetic acid ] (Sigma 
Chemical Co. , St. Louis, �) was dissolved in 30 ml of glass distilled 
water and neutralized with 4 N KOH to pH 7. 0. The volume was then made 
to 50 ml with glass distilled water in a volumetric flask. 
15. Radioactive Acetyl CaA mix (0. 1 nf.1 [ 1-1 4C] acetyl CoA 
solution : 2 volumes of [ 1-1 4C ] acetyl CoA (#7) were mixed with 1 
volume of 0. 1 mM acetyl CoA (#10) and kept on ice. 
16. Reagent mixture for each assay : 
MJPS (0. 1 M) buffer pH 7. 4 (#12) 
EGTA (0. 1 M)  pH 7. 0 (#15) 
�2
s
4
o6 (0. 1 M) (#5) Raaioactive acetyl CoA mix (0. 1 M) 
(#16) 
Glass distilled water 
120 µl 
20 µl 
20 µl 
200 µl 
40 µl 
17. Bovine serum albumin ( 8% Fraction V, fatty acid poor from ICN 
Nutritional Biochemicals, Cleveland, OH) : 4 g of BSA was dusted into 
about 20 ml of glass distilled water and stirred. The volume was made 
to 50 ml with gl� distilled water in a volumetric flask. 
18a. Scintillation fluid A: 33 g of PPO (2, 5-diphenyloxazole) and 
1 g of POPOP (1 , 4-Bis [2-{ 5-Phenyloxazolyl}benzene] )  were dissolved in 4 
liters of toluene (C6H5
CH3). 
18b Scintillation fluid B: 2 parts of scintillation fluid A 
(#18a) was mixed with 1 part Triton X-100 (Fisher Scientific Co. , Fair 
Lawn, NJ ) .  
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2 . Procedure 
Carnitine standards and samples were prepared in 12  x 75 nun Pyrex 
glass test tubes as shown in Table 2. Standard and sample tubes were 
vortexed and then centrifuged at 4 ° for 10 minutes at 1500 x g using a 
Beclonan centrifuge ( Beckman Instruments, Palo Al to, CA) • The 
supernatant fluid was used to quantitatively determine the 
concentrations of non-esterified carnitine (NEC), and acid-soluble 
acylcarni tine ( ASAC) . The ASAC fraction was calculated by subtracting 
NEC from the total ASAC . The pellet was used to quantitate the 
concentration of acid-insoluble acylcarnitine (AIAC) . The NEC, ASAC, 
and AI.AC are equivalent to the free carnitine, short-chain 
acylcarnitines, and the long-chain acylcarnitines respectively, 
described in the literature. 
Table 2 .  Standard Mixtures of Carnitine 
CNE�td1 L-cNE:2 P-cNE:3 �4 
(µl) ( nm) ( nm) ( µl ) 
0 
10 
20 
30 
40 
60 
0 
0 
1. 25 
2 . 50 
3 . 75 
5 . 00 
7 . 50 
0 
0 
1. 15 
2 . 30 
3 . 45 
4 . 60 
6 . 90 
0 
100 
90 
80 
70 
60 
40 
125 
; carnitine standard mix 
3 
L-carnitine (non-esterified) 
4 L-palmitoylcarnitine 
5 glass distilled water 
6 bovine serum albumin perchloric acid 
8%5 
BSA 
(µl) 
100 
100 
100 
100 
100 
100 
25 
0 . 6e,M 
PCA 
(µl) 
200 
200 
200 
200 
200 
200 
200 
Plasma 
(µl) 
0 
0 
0 
0 
0 
0 
50 
Total 
(µl) 
400 
400 
400 
400 
400 
400 
400 
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a. Non-esterified carnitine (NEC) Detemination 
A 150 µl portion of the PCA supernatant fluid was transferred to 
12 x 75 mm phenol red pyrex test tubes and neutralized with 35 µl 1 M 
KHC03. The tubes were placed on ice and allowed to stand at least 30 
minutes until ready to assay for carnitine. 
b. Acid-soluble Acylcarnitine (ASAC) Determination 
A 100 µl portion of the PCA supernatant was transferred to 12 x 75 
mm phenol red Pyrex test tubes. Alkaline hydrolysis was achieved by 
adding 75 µl of 0. 5 N KOH and then incuJ::ating at 37 ° for 30 minutes. 
Tubes were then neutralized with 30 µl PCA-l'<>PS II, then placed on ice 
for 30 minutes until ready to assay for carnitine. 
c. Acid-insoluble Acylcarnitine (AIAC) Determination 
The pellets were drained of any remaining PCA supernatant and 
washed twice by resusperr:iing in 0. 6 M PCA. An intact pellet was 
regained after each wash by centrifuging at 1500 x g for 10 minutes. 
One drop of phenol red indicator was placed in each tube. Alkaline 
hydrolysis of the the PCA supernatant-free pellets was accomplished by 
- adding 200 µl 0.5 N KOH and then incubating in water bath at 65 ° for 60 
minutes. Tubes were then neutralized with 100 µl PCA-MOPS I and the 
tubes were then placed on ice at least 30 minutes until ready to assay 
for carnitine. 
d. Assay for Carnitine 
A 100 µl portion was transferred from each of the appropriate 
fractions for non-esterified carnitine, acid-soluble acylcarnitine and 
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acid-insoluble acylca.rni tine into 1. 5 ml capacity microtu.bes. Four 
hundred µl of reagent mixture and 20 µl (1 Unit ) of carnitine 
acetyltransferase were added to initiate the enzymatic reaction for 
[ l- 1 4 C]acetylcarnitine formation. The tubes were capped, gently mixed 
by agitation, then placed in a 37 ° water l:ath for a 30 minute 
incubation period. After this, a 200 µl aliquot of the incubation 
mixture was placed on a 4.5 an anion exchange minicolUJlll'l (columns were 
made by packing Dowex 1 x 8, 200-400 mesh, c1- into a 0.5 x 5.75 inch 
glass pasteur pipette ) .  After the sample was adsorbed on the anion 
exchange resin, the columns were eluted with 2 portions of 500 µl glass 
distilled water into a 20 ml-capacity scintillation vial (New England 
Nuclear, Boston, MA) . The eluate was mixed with 10 ml of scintillation 
fluid B, capped, gently mixed by swirli�, and then placed into a 
liquid scintillation counter (Beckman models LS lOOC and/or LS 3801, 
Beckman Instruments, Palo Alto, CA) to evaluate the radioactivity in 
each vial. The concentration of the carnitine standards was plotted 
against the radioactive counts for each standard. A standard curve 
was plotted and the inverse slope of the standard curve was estimated 
from this plot . . 
Garnitine concentration of each fraction was determined as follows: 
carnitine concentration (nmol/ml) = IS * (CPM
sample 
- �lank) * df 
where: IS = inverse slope of the standard curve, 
CPM = counts per minute, and 
df = dilution factor ( = 20 ) .  
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Total ca.rnitine (TC): the total carnitine concentration was the 
mathematical sum of the three fractions of carnitine , i.e., 
TC = NEC + ( total ASAC - NEC) + AIAC. , 
C. Infant Formula carnitine Determination 
The carnitine content of Portagen, Enfamil-Prema.ture Formula , and 
Enfamil-20 were determined according to the procedure for plasma 
carnitine determination. The only toodifications were: (1) an 
appropriately diluted 100 µ1 sample , instead of the 50 µ1 plasma sample, 
and (2) the determinations were done in triplicate. The average 
carnitine concentration used for calculations of carnitine intake. 
D. Plasma Non-Esterified Fatty Acid Det�rmination 
The determination of plasma non-esterified fatty acids was based 
on the method of Novak ( 86) . The plasma NEFA may be extracted with a 
mixture of isopropyl alcohol and heptane. The extracted lipids will 
react with cobalt to form cobalt soaps. The cobalt soaps will give a 
color reaction when mixed with a-nitroso-,9-naphthol which can be 
measured spectrophotanetrically at 500 nm. 
1. Reagents 
1. Saturated K
2
so
4 
solution: K
2
so
4 
was added to boiling water 
until saturated. The solution was stored in contact with the extra 
crystals overnight , and then filtered. 
2 .  Cobalt nitrate-acetic acid-potassium sulfate solution: 6 g of 
�(N03)2 • 6H2o and 0. 8 ml of glacial acetic acid were mixed with the 
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saturated K
2
so
4 
solution (#1), and the volume was brought to 100 ml in 
a volumetric . flask. The contents were stored at 37 °. 
3. Saturated Na
2
so4 solution: Na2so4 was added to boiling water 
tmtil saturated. The solution was stored in contact with the extra 
crystals overnight, and then filtered. 
4.. Cabal t reagent : 1. 35 volumes of triethanolamine, 10 volumes 
of the cobalt nitrate-acetic acid-potassium sulfate solution, and 7 
voltunes of the saturated Na2so4 solution were mixed together in a 
glass beaker. This reagent was made fresh every series of analyses. 
5. Indicator solution (stock solution): 400 ng of 
a-nitroso-�-naphthol was dissolved in 96% ethanol. A working solution 
was made fresh for each series of analyses by diluting the stock 
solution by a factor of 12.5 before use. 
6. Dole ' s  extraction mixture: 40 volumes of redistilled 
isopropyl alcohol, 10 voli..unes of redistilled heptane, and 1 volume of 
1 N H2so4 were mixed together and the contents were stored at room 
temperature. 
7. Palmitic acid standard (0.4 meq/dl): 10.24 ng of palmitic 
acid was dissolved in 100 ml of Dole's extraction reagent and was 
stored at -20 °. 
8. Chloroform-Heptane mixture: 5 volumes of redistilled 
chloroform was mixed with 1 volume of redistilled heptane and stored 
at 20 °c tmtil use. 
2 . Procedure 
The blank and standard test tubes were prepared by adding 250µ1 of 
Dole's extraction reagent or 250 µl of palmitic standard to their 
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respective tubes. A volume of 50 µl of glass distilled water was added 
to each of the blank and standard tubes. Samples of unknown NEFA 
concentrations were prepared by adding 50 µl of plasma to 250 µl of 
Dole 1 s extraction reagent. All tubes were vortexed and then placed in 
melting ice water for 10 minutes. A volume of 400 µl of heptane and 
500 µl of glass distilled water was added to each tube. All tubes 
were then vortexed. to allow separation of phases. After this, 300 µl 
of the upper heptane phase was transferred to a 1 . 5  ml-capacity 
plastic microtu.be . This was followed by the addition of 500 µl of the 
chlorofornnn-heptane mixture and 500 µl of cobalt reagent. The tubes 
· were placed in an automatic shaker and vigorously mixed for 3 minutes. 
The microtubes were then centrifuged at 1800 x g for 15 minutes. 
After centrifugation, 600 µl of the chloroform-heptane phase was added 
to 12  mm x 75 nm glass test tubes which contained 750 µl of the 
working indicator solution. The tubes were allowed to stand at room 
temperature for 30 minutes for color developnent. Next, the 
absorbance of each tube was read against the blank at 500 nm. A 
standard curve was plotted and the inverse slope was estimated from 
the standard curve. The quantification of NEFA of � plasma unknowns 
was determined as follows: 
NEFA (meq/1) = A ( unknown ) * IS *  df 
where : A = absorbance at 500 nm, 
IS = inverse slope of the standard curve, and 
df = dilution factor ( = 20 ) . 
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E. Statistical Methods 
The Students "t" test (87) was utilized to evaluate maternal , 
umbilical cord , and infant carnitine ar..d triglyceride levels. Simple 
Regression , utilizing the method of regression of least squares was 
used to determine all correlation coefficients (r), and the 
significance was determined by an Analysis of Variance. A statistical 
software package (Statgraphics, Statistical Graphics Corporation) was 
used for all regression statistics. The Students "t" test for paired 
comparisons (88) was used to evaluate the effects of nutritional 
intervention on carnitine and triglyceride levels . For all data 
analyzed, the minimal level of statistical significant acceptance 
was p<0. 05. 
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CHAPTER IV 
RESULTS 
A. Plasma Garnitine at Birth 
1. Maternal, Umbilical Cord and Infant Plasma carnitine L-evels 
The maternal, umbilical cord, and infant mean plasma carnitine 
and triglyceride concentrations obtained within 8 hours post-partum are 
presented by group in Figure 1 and in Tables 3 and 4. The values were 
com:pared between and within each group. Both paired and unpaired 
maternal, cord, and infant data are listed in the tables. Since paired 
data were limited (Table A-2), the unpaired data were incorporated into 
the text of the results and the discussion will be focused on the 
analysis of the unpaired data. 
Maternal NEC and TC in Groups I and II were significantly higher 
when compared with Groups III and r.v. There was no difference in 
maternal CNE between either Group I and II or Group III and Group r.v 
( reference group) . The maternal plasma levels of ASAC were not 
significantly different between the control and experimental groups. 
The maternal plasma levels of long-chain AIAC were similar in all 
groups except Group I, which had significantly higher AIAC levels 
compared to the other groups. 
The umbilical cord levels of NEC, ASAC, and CNE were similar in 
all groups. However Groups I, II, and III had significantly higher 
mean levels of AIAC than the control group. 
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Table 3 . Plasma Carnitine Levels
1
'
2 (nmol/ml) at Birth3 for Maternal, 
Umbilical Cord, and Infant Plasma (Unpaired). 
Group Maternal 
Total Carnitine 
I 22. 5 ± 3 . 3 a, f 
II 29 . 9  ± 4 . 5  a, fg 
III 16. 4 ± 1 . 6  b, g 
IV 16 . 4  ± 1 . 0  b, g 
Non-Esterified Carnitine 
I 19 . 4  ± 2 . 4  a, fg 
II 22 . 7  ± 3 7 a, fg 
III 10 . 7  ± o : 6 
b, h 
0 . 8  
b, g IV 12 . 2  ± 
Acid-Soluble Acylcarnitine 
I 5 . 5 ± 1 . 4  
a, f 
II 6. 2 ± 1. 1 
a, f 
III 4 . 7  ± 1. 1 
a, f 
IV 3. 6  ± 0 . 6  
a, f 
Acid-Insoluble Acylcarnitine 
I 
II 
III 
IV 
1 
1 . 6  ± 0 . 1 ab
, f
f 1 . 1 ± 0. 1 I 
1 . 0  ± 0. 3 � , � 
0.8 ± 0. 1 I 
Cord 
21 . 9  ± 4 . 5  
a, f 
24 . 3 ± 1 . 9  
a, g 
1. 6 
a, f 22 . 7  ± 
1. l 
a, f 20 . 3 ± 
14 . 8  ± 3. 5  a, g 
16 . 5  ± 1 . 1 a, g 
15 . 8  ± 3 . 2  a, g 
15 . 0  ± 0 . 7  
a, f 
6 . 5  ± 1 . 1 
a,
� 
6 . 3 ± 1. 9 .a, f 5 . 6  ± o.'a 
a,
f 
4 . 4  ± 1 . 0  a, 
1. 2 
1. 5 
1 . 2  
0. 0 
a, g ± 0 . 1 f 
± 0 . 2  
a,
f ± 0.l � ' f 
± 0 . 1 I 
Infant 
32 . 7  ± 3 _ 4  ab, f 
36 . 1 ± 4 4 a, f 
26 . 3 ± 2 : 2 bc, f 
21 . 0  ± 1 . 4 c, f 
25 . 3 ± 3 _ 1 
ab, f 
29 . 5  ± 3 0 
a, f 
20 . 2  ± 1 : 1 b, f 
15 . 2  ± 1 . 1 
c ,  fg 
6 . 4  ± 0 . 5  a, f 
6 . 4  ± 1 .  2 
a, f 
5 . 3 ± 2 . 6  
a, f 
5 . 2  ± 0. 7 
a, f 
1 . 0  ± 0 . 1  a,� 
1 . 2  ± 0. 2 a,
f 
0 . 9  ± 0 . 1 
a, 
0 . 7  ± 0 . 1 
a, f 
2 Values are the group means ± SEM 
Means in a row or column without a common superscript letter are 
3 different ( p<0.05) Plasma samples were obtained within 8 hours post-partum 
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Table 4. Plasma Triglyceride Levels (ng/dl)
1 ' 2 at Birth
3 for 
Maternal, Umbilical Cord, and Infant Plasma ( Unpaired) .  
Group Maternal Cord Infant 
I 151 ± 33 
a, g 39 ± 11 a, f 31 ± 5 ab , f  
II 216 ± 51 a, g 36 ± 6 a, f 29 ± 3 a, f 
III 168 ± 23 a, g 19 ± 2 b, f 19 ± 3 b, f 
IV 175 ± 27 a, g 30 ± 5 a, f 26 ± 15 ab , f  
1 Values are the group means ± SEM 
2 Means in a row or column without a common superscript letter are 
different ( p<0.05) 
3 Plasma samples were obtained within a hours post-partum 
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The infant plasma levels of NEC were higher in the premature 
infants compared with the term (Group IV) infants, and Groups I and II 
had significantly higher NEC levels than Groups III (the oldest 
premature infants). The plasma TC levels were highest in Group II, 
although Group I was no� significantly different than Group II. Like 
NEC, the premature infants had higher TC levels than the controls, 
while only Groups I and II were significantly higher than the 
controls. There were no significant differences among groups for 
either ASAC or AIAC (Table 3). 
Intra-group comparisons of maternal, umbilical cord, and infant 
carnitine are also presented in Table 3. In all groups, the infant 
NEC and TC levels were higher than the maternal and umbilical cord 
levels. Within a group, the differences of NEC were variable. There 
was not difference between the NEC levels of the maternal and umbilical 
cord or the umbilical cord and the infant. In Group III and IV, the 
NEC levels were significantly higher in umbilical cord and infant, 
canpared to the maternal plasma. In Group IV, maternal and umbilical 
cord NEC levels were different (p<0. 05) while infant levels of NEC 
were not different between the maternal and umbilical cord levels. 
The maternal, umbilical cord, and infant ratio (M:C:I ratio) of TC 
within each of the three groups is presented in Table A-4. The ratio 
of maternal, cord, and infant carnitine values were not identical 
between any group. The ratio of maternal TC was higher than umbilical 
cord TC in Groups I and II, but in Groups III and IV the ratio of 
umbilical cord to maternal CNE was higher. 
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2. Relationship Between Gestational Age and carnitine Levels at Birth 
The relationship of infant plasma carnitine levels at birth 
comi;:ared to gestational age is presented in Figures 2 and 3 .  There was 
a decrease in plasma TC (r=-0. 4418, p<0. 01) with advancing gestational 
age. However, there was an increase in TC at birth (r=0. 7278, p<0. 005), 
in infants of gestational age 24. 5-31. 5 weeks. After this time the TC 
levels decreased to an apparent plateau at approximately 20 nmol/ml by 
34 weeks. The changes in NEC paralleled those of TC. There was not a 
significant correlation. of ASAC or AIAC with advancing gestational age. 
B. Changes in Carnitine and Triglyceride With Postnatal Age 
The mean carnitine and triglyceride levels with advancing 
gestational age are presented by group in Figures 4-6. During the 
first week post-i;:artum, all three groups exhibited a decrease in NEC 
and TC levels. The greatest decrease occurred in Group II, follc:Med 
by Group III, and the smallest decrease occurred in Group I. With 
time, all grou:ps exhibited an increase in total carnitine levels. 
Group III achieved birth carnitine levels by day 7, Group II on day 
28, and Group I on day 91. The increase in plasma carnitine coincided 
with the initiation of a carnitine-containing diet. 
No infant received dietary carnitine before plasma samples W1ere 
obtained for days O and 1. During the first 24 hours post-partum, the 
percent mean change in TC levels were as follows : Group I +5%, Group II 
-24%, and Group III -9%. By day 5, the percent changes of TC W1ere -5%, 
-41%, and -7% for Groups I, II, and III, respectively. However, by 
day 7, the percent mean changes were -21%, -34%, and +15%, respectively. 
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After the first post-partum week, Group I infants continued to 
show a decrease in TC until day 42 at which time the TC level was 5.2 
nmol/ml. These infants did not obtain birth TC levels until day 91 
( 30.4 nmol/ml). After this the TC level continued to rise and was 60 . 4  
nmol/ml on day 112. Infants in Group II also showed a decrease in TC 
during the first week and then a rise until day 28 { 28.6 nmol/ml } . The 
TC level plateaued on day 28, then increased after day 56 to a final 
value of 69.4 nmol/ml on day 84. Infants in Group III continued to 
show a steady increase of TC from day 7 until day 21. After this, the 
level of CNE appeared to plateau at about 38-43 nmol/ml until all 
infants had been discharged on day 42. 
In all groups, NEC paralleled the changes of TC (Figure 4) . Since 
NEC and ASAC are influenced by the metabolic state, by the ability of 
the infant to utilize fat, and dietary factors, these levels are used 
together and stated as the NEC to ASAC ratio (the NEC :ASAC ratio was 
calculated from the data points shown in Figure 4). The daily NEC:ASAC 
ratio was similar in each group at birth { 3. 97, 4.58, and 3.83 in 
Groups I, II, and III, respectively) and also throughout the study. 
The NEC:ASAC ratio decreased in all groups during the first few days 
of life. The ratio remained below the birth value until days 56, 49, 
and 14 in Groups I, II, and III, respectively. 
The group means of AIAC followed similar patterns throughout the 
study. All groups had similar AIAC levels at birth. The AIAC peaked 
within the first week of life in each of the three groups. AIAC in 
Groups II and III each peaked on day 1, while Group I AIAC began to 
increase on day 1, (AIAC did not peak until day 3). Group I retained 
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the peak levels longer, 3 days, while the other two groups had a peak 
which lasted only one day. 
The changes in TG levels with advancing age showed a similar trend 
in all groups. 'Ihe TG levels showed a continuous increase during the 
first 14 days. After this, TG levels remained relatively constant. 
The mean TG in Group I appeared to plateau at approximately 85 mg/dl, 
in Group II at 80 ng/dl (with more fluctuation than the other groups), 
and in Group III, at a�roximately 105-110 mg/dl. 
C. carnitine Content of Infant Formula 
The results of the carnitine determination on the conunercial 
infant formulas used in the study are presented in Table 5. Th.ere was 
no detectable carnitine in Portagen (soy protein-based formula) .  
There were substantial amounts -of carnitine in Enfamil-PF and in 
Enfamil-20 (lx>th are milk-based formulas). The average total 
carnitine was 327 nmol/ml in Enfamil-PF and 184 nmol/ml in Enfamil-20. 
D. Relationship of . Plasma carnitine anci ' Triglyceride 
with Various Nutritional Interventions 
1 .  Carnitine and Triglyceride Levels After Total Parenteral Nutrition 
The changes in carnitine and triglyceride after total parenteral 
nutrition (TPN) are presented in Table 6 and Figure A-1. In all three 
groups, the concentrations of NEC, ASAC, AIAC, and TC decreased after 
infants had received TPN for 24 hours. Only Groups II and III had a 
significant decrease in NEC and TC. However, the mean decreases in NEC 
and TC were greater · in Group I than in Group II or Group III. A 
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Table 5. Carnitine Content of 1 2 Infant Formulas ' 
Carnitine 
Fraction Portagen Enfamil-PF 
�"'EC ND
3 270 ± 1 
ASAC ND 56 ± 3 
AIAC ND 1 ± 0 
TC ND 327 ± 3 
1 Values are reported in nmol/ml of formula 
2 Values are the mean ± SEM 
3 Non-detectable 
Enfamil-20 
155 ± 3 
34 ± 2 
0 ± 0 
184 ± 3 
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Table 6. Plasma carnitine and Triglyceride Levels
1 
Before , 24 Hou.rs 
After Initiation, and Upon Discontinuation of Total 
Parenteral Nutrition. 
Parameter Group n Pre-TPN 24 ° Post-TPN Post-TPN
2 
NEC
3 
I 8 24. 9 ± 4. 2  16. 5 ± 2. 9 4. 9 ± 0. 5 
a 
II 10 1 8. 6  ± 2. 7 15. 5 ± 1. 9 a 9. 8 ± 1. T a 
III 9 15. 7 ± 1 . 5  11. 9  ± 1. 4  a 13 . 8 ± 1 . 1  
ASAC
4 
I 8 10. 4  ± 2. 3 6. 6 ± 1. 4 2. 7 ± 0. 5 
a 
II 10 5. 6 ± 1. 0 5. 9 ± 0. 8 4 . 0 ± 0. 8 
III 9 5. 5 ± 0. 5 3. 2  ± 1. 0 a 3. 6  ± 0. 5 
AIAC
5 
I 8 1. 3 ± 0. 4 0. 9 ± 0 :1 0 . 5  ± 0. 2 
a 
II 10 1. 1 ± 0. 3 0. 7 ± 0 . 1 0 . 7 ± 0 . 2  
III 9 1. 6  ± 0. 2 1. 1 ± 0. 2 
a 
0 . 8  ± 0. 1 
TC6 I 8 36. 3 ± 6. 5 24. 1 ± 4 . 3  8 . 2  ± 0. 7 a 
II 10 25. 4 ± 2. 2 21 . 6  ± 2. 8 a 14 . 5  ± 2. 4 a 
III 9 22. 8 ± 2 . 4  16. 3 ± 1 . 9  
a 
18. 2  ± 1. 4 
a 
TG
7 
I 8 55. 6 ± 9. 5 41 . 5  ± 3. 7 84. 0 ± 17. 4  
II 10 51. 2 ± 4 . 5  43 . 2  ± 4. 9
a 
58. 0  ± 12. 6 
III 9 49. 1 ± 5. 6 59. 7 ± 7. 8 55. 0 ± 18. 6  
Fat I 8 0. 00 ± 0. 00 ± 4 . 1 1 ± 0. 24 
Intake
8 
II 10 0. 30 ± 0. 20 0. 48 ± 1. 01 3. 28 ± 0. 55 
III 9 0. 26 ± 0. 20 0. 50 ± 0. 34 1. 32 ± 0 . 57 
1 
2 
Values are the means ±  SEM 
Values are the mean levels after the discontinuation of TPN; or if 
the infant received a CNE-containing formula prior to the discon­
tinuation of TPN, the values is the mean plasma level prior to the 
3 
provision of the CNE-containing formula 
4 
Non-esterified carnitine (nmol/ml ) 
5 
Acid-soluble acylcarnitine (nmol/ml ) 
6 
Acid-insoluble acylcarnitine (nmol/ml ) 
7 
Total carnitine (nmol/ml ) 
8 
Triglyceride (mg/dl ) 
Fat intake (g/kg/day) 
a 
pre-TPN and post-TPN values are different 
a p<0. 05 level 
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significant decrease of ASAC was seen only in Group III. The NEC :ASAC 
ratio increased in Groups I and III , while at the same time it 
decreased in Group II (Table A-5) 
The levels of NEC and TC decreased in Groups I and II throughout 
TPN administration. However , in Group III , the levels of NEC , ASAC , 
and TC were increased from the 24 hour post-TPN levels , but were still 
below pre-TPN levels. Upon discontinuation of TPN (Post-TPN) , the TC 
levels were 8.2 , 14.5 , and 18.2 nmol/ml for Groups I ,  II , and III , 
respectively. These values compared with the pre-TPN values of 36.3 , 
25.4 , and 22.8 nmol/ml and the 24 hour post-TPN values of 24. 1 ,  21.6 , 
and 16.3 nmol/ml for each of the respective groups. The mean numbers 
of days that each group received TPN (before administration of a 
carnitine-containing formula) were 35. 0, 13. 5 ,  and 5.5 , respectively . 
. The only significant change in the plasma TG level at 24 hours 
post-TPN occurred in Group II where there was a decrease of TG. There 
were no significant changes in plasma triglyceride upon discontinuation 
of TPN. 
2. carnitine and Triglyceride Changes After Intravenous Fat Emulsion 
Administration 
The changes in carnitine and TG levels after administration of 
intravenous fat emulsion are presented in Table 7 and Figure A-2. 
There were no significant changes in any of the carnitine fractions 24 
hours after continuous infusion of intravenous fat enru.lsion when 
compared to pre-fat infusion values. However , all groups showed an 
increase in the mean concentrations of NEC and TC. Only Group III had 
an increase in the mean ASAC level , while the other two groups showed 
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Table 7 .  · Plasma carni tine and Triglyceride Levels
1 
Before and 
Hours After Ini tiation of Intravenous Fat Emulsion . 
Parameter Group n Pre-Fat 
NEC
2 
I 8 18 . 7 ± 3 . 3  
. II 6 15 . 0  ± 2 . 0 
III 3 1 1 . 0  ± 2 . 7  
ASAC
3 
I 8 6 . 4  ± 2 . 1 
II 6 5 . 9  ± 2 . 3  
III 3 2 . 4  ± 1 . 0  
AI.AC
4 
I 8 1 . 2  ± 0 . 3  
II 6 0 . 7  ± 0 . 1 
III 3 I 0 . 8  ± 0 . 2  
TC
5 
I 8 26 . 7  ± 4 . 6 
II 6 21 . 6  ± 2 . 3 
III 3 14 . l  ± 3 . 9  
TG
6 
I 8 56 . 2  ± 10 . 0  
II 6 43 . 2  ± 6 .4 
III 3 44 . 7  ± 4 . 8  
Fat 
7 
I 8 0 . 00 ± 
Intake II 6 0 . 18 ± 0 . 18 
III 3 0 . 00 ± 
; Values are the means ± SEM 
3 
Non-esterified carnitine (nmol/ml ) 
4 Acid-soluble acylcarnitine (n100l/ml) 
5 
Acid-insoluble acylcarnitine (nmol/ml) 
6 
Total carnitine (nmol/ml) 
7 
Triglyceride (ng/dl ) 
Fat intake (g/kg/day) 
a 
pre-fat and post-fat values are different 
at p<0 . 05 level 
Post-Fat 
19 . 8  ± 2 . 7  
19 . 2  ± 3 . 0  
12 . 1 ± 3 . 4 
4 . 7  ± 2 . 7  
3 . 7  ± 0 . 6  
3 . 3  ± 0 . 5  
1 . 2  ± 0 . 2  
0 . 7  ± 0 . 2  
0 . 6  ± 0 . 1 
28 . 8  ± 5 . 0  
23 . 7  ± 3 . 3  
17 . 8  ± 2 . 2  
75 . 9  ± 10 . 9  
a 
46 . 5  ± 1 1 . 0  
46 . 0  ± 10 . 5  
0 . 32 ± 0 . 07 
0 . 32 ± 0 . 17 
0 . 24 ± 0 . 1 3 
24 
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virtually no change in ASAC. The mean NEC:ASAC ratio decreased in 
both Groups I and III, but increased in Group II ( Table A-5). There 
were no significant changes of AIAC in any group when compared to the 
pre-administration levels . 
The plasma TG concentration remained constant in both Groups II 
and III during the 24 hours of fat administration. Only Group I had a 
significant increase in plasma triglyceride with administration of 
intravenous fat emulsion. However, Group I also had the largest 
increase in the mean total fat intake than either of the other groups. 
3. Changes of Carnitine and Triglyceride After Portagen Feedings 
The carnitine and TG changes 'before and after achievement of full 
strength Portagen are presented in Table 8 and Figure A-3. The NEC and 
TC levels decreased in Groups I and II, but had not changed in Group 
III when compared to the pre-Portagen plasma levels. The NEC:ASAC 
ratio decreased in all groups during the administration of Portagen 
( Table A-5) . There were no significant changes of ASAC, AIAC, or TG 
at 24 hours after full strength Portagen feedings when compared to the 
pre-Portagen values. 
4 .  Changes of Carnitine and Triglyceride After Enfamil-Premature 
Formula Feedings 
The carnitine and TG levels 'before and at 24 hours after 
achievement of full strength Enfamil-Premature Formula (Enfamil-PF) are 
presented in Table 9 and Figure A-4. These values reflect only infants 
in Groups I and II, as no infant in Group III received Enfamil-PF. The 
mean levels of TC, NEC, and TG were increased in both groups when 
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Table 8. Plasma carnitine and Triglyceride Levels
1 
Before and After 
Initiation of Full Strength Portagen. 
Parameter Group n Pre-Portagen Post-Portagen 
NEC
2 
I 5 17. 9 ± 3.1 
II 8 17. 7 ± 2. 3 
III 2 1 3. 4  ± 1. 0  
ASAC3 I 5 4. 7 ± 0 . 9  
II 8 3. 6  ± 0. 4 
III 2 2. 2 ± 0.7 
AIAC
4 
I 5 0. 9 ± 0. 2 
II 8 0 . 8  ± 0.2 
III 2 0. 9 ± 0. 2 
TC
5 I 5 2 3. 5 ± 3. 6  
II 8 2 1. 6  ± 2. 1 
III 2 18. 7 ± 1. 8  
TG
6 I 5 63.4 ± 8. 9 
II 8 61.9 ± 1 1. 0  
III 2 44 . 5  ± 4.0 
Fat 
7 
I 5 0. 37 ± 0. 13 
Intake II 8 0. 54 ± 0 . 16 
III 2 0 . 00 ± 
; Values are the means ± SEM 
3 
Non-esterified carnitine (rm:,1/ml ) 
4 
Acid-soluble acylcarnitine (rm:,1/ml ) 
5 Acid-insoluble acylcarnitine (rm:,l/ml ) 
6 
Total carnitine (nmol/ml ) 
7 Triglyceride (m;r/dl ) Fat intake (g/kg/day) 
, 
5. 1 
10. 5 
10. 9 
2.7 
4 . 3 
3. 4  
0. 6 
0. 5 
0. 9 
8. 5 
15.3 
15. 2  
58. 4 
87. 2 
1 1 3. 4  
4. 16 
3.85 
1. 08 
a pre-Portagen and post-Portagen values are different 
at p<0. 05 level 
± 0. 9 
a 
± 1. 9  
a 
± 0. 2 
± 0. 5 
± 0 . 7  
± 0. 7 
± 0.'2 
± 0.1 
± 0. 2 
± 1. 4  
a 
± 2. 5 
a 
± 1 . 2 
± 3. ·1 
± 17. 3 
± 64.8 
± 0. 34 
± 0.1 6 
± 1 . 1 1  
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Table 9. Plasma Carnitines and Triglyceride Levels
1 
Before and 
24 Hours After Initiation of Full Strength Enfami�-
Premature Fornru.la. 
Parameter Group n Pre-E..'1.famil-PF Post-Enfamil-PF 
NEC
2 
I 3 5. 4 ± 1. 0  
II 2 10. 0 ± 5. 8 
III 0 
ASAC
3 
I 3 0. 9 ± 0. 6 
II 2 5. 4 ± 1. 5  
III 0 
AIAC4 I 3 0. 3 ± 0. 1 
II 2 1. 1 ± 0. 7 
III 0 
TC
5 
I 3 6. 5 ± 1. 6  
II 2 16. 5 ± 8. 0 
III 0 
TG
6 I 3 93 . 0  ± 14 . 6 
II 2 56. 0 ± 12. 0  
III 0 
Fat I 3 3. 75 ± 0 . 52 
Intake
7 
II 2 1 . 95 ± 1 . 14 
III 0 
1 
2 
Values are the means ±  SEM 
3 
Non-esterified carnitine (rm:>1/ml) 
4 Acid-soluble acylcarnitine (nmol/ml) 
5 Acid-insoluble acylcarnitine (nmol/ml) 
6 Total carnitine (nmol/ml) 
7 Triglyceride (ng/dl) Fat intake (g/kg/clay) 
18. 0 ± 
22. 7 ± 
4. 7 ± 
5. 5 ± 
0. 6 ± 
0. 5 ± 
22 . 4  ± 
28. 8 ± 
102. 7  ± 
89. 0 ± 
5. 23 ± 
4 .. 71 ± 
a 
pre-Enfamil-PF and :pJSt-Enfamil-PF values are different 
at p<0. 05 level 
4. 7 
6 . 5 a 
1. 8  
1. 2 
0. 2 
0. 5 
8. 1 
8. 5 
a 
32 . 7  
42. 0 a 
0. 17 
0. 62 
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compared to the pre-Enfamil-PF levels. The NEC:ASAC ratio decreased in 
Group I while at the same time, the ratio increased in Group II. The 
levels of ASAC and AIAC had not significantly changed in either group 
when compared to the pre-Enfamil-PF plasma levels. 
5. Changes of Carnitine and Triglyceride After Enfamil-20 feedings 
This classification consists only of infants which received 
Enfamil-20 as their first carnitine-containing fonnula. All infants 
who had received Enfamil-PF or breastmilk prior to Enfamil-20 feedings 
were excluded. The carnitine and TG changes after Enfamil-20 feedings 
are presented in Table 10 and Figure A-5. The concentrations of NEC, 
ASAC, AIAC, and TC were increased 24 hours after achievement of full 
strength Enfamil-20. The mean NEC, ASAC, TC, and TG levels were 
increased in both groups when canpared to pre-Enfamil-PF levels. The 
mean AIAC level was increased in Groups I and III, while at the same 
time it remained constant in Group II . The NEC:ASAC ratio was 
increased in both Groups I and II, but was decreased in Group III when 
comi;ar� to pre-Enfamil-20 values (Table A-5 ) .  The TG level was 
wignificantly higher in Group III, while no significant changes were 
seen in either Group I or Group II in the post-Enfamil-20 sampling. 
6. Changes of Garnitine and Triglyceride After Breastmilk Feedings 
Plasma carnitine, and TG levels before and after breastmilk 
feedings are presented in Table 11 and Figure A-6. The values include 
infants from Groups II and III only, as there were no infants in 
Group I who received breastmilk in the study. The levels of NEC, 
ASAC, AIAC, TC, and TG all increased from the pre-breastmilk values. 
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Table- 10 .  Plasma Garnitine and Triglyceride Levels
1 
Before and 24 
Hours After the Initiation of Full Strength Enfamil-20 . 
Parameter Group n Pre-Enfamil-20 Post-Enfamil-20 
NEC
2 I 3 3 . 0  ± 0 . 8  
II 6 7 . 9  ± 1 . 6 
III 14 1 2 . 6  ± 1 . 1  
ASAC
3 
I 3 1 . 3 ± 0 . 2 
II 6 3 . 8  ± 0 . 6  
III 14 4 . 2  ± 0 . 5  
AIAC4 I 3 0 . 1 ± 0 . 0  
II 6 0 . 5  ± 0 . 2  
III 14 0 . 9  ± 0 . 2  
TC5 I 3 4 . 4  ± 0 . 5  
II 6 12 . 3  ± 2 . 2 
III 14 17 . 7  ± 1 . 3 
TG6 I 3 52 . 7  ± 1 . 5  
II 6 72 . 9  ± 20 . 5  
III 14 39 . 0  ± 8 . 4 
Fat I 3 
Intake
7 II 6 4 . 44 ± 0 . 25 
III 14 0 . 04 ± 0 . 03 
1 
2 Values are the means ±  SEM 
3 
Non-esterified carnitine (nmol/ml) 
4 Acid-soluble acylcarnitine (nmol/ml) 
5 
Acid-insoluble acylcarnitine (nmol/ml) 
6 
Total carnitine (nmol/ml) 
7 
Triglyceride (ng/dl) 
Fat intake (g/kg/day) 
12 . 0  = 
23 . 1 ± 
18 . 6  ± 
4 . 0  ± 
6 . 9  ± 
8 . 1  ± 
0 . 3 ± 
0 . 5  ± 
1 . 0 ± 
15 . 3 ± 
32 . 6  ± 
27 . 7  ± 
55 . 0  ± 
1 16 . 2 ± 
102 . 5  ± 
6 . 00 ± 
4 . 31 ± 
a 
pre-Enfamil-20 and post-Enfamil-20 values are different 
at p<0 . 05 level 
1 . 0 
a 
3 . 9  
a 
1 . 3  
a 
1 . 1  
1 . 0  
a 
0 . 9  
a 
0 . 0  
0 . 1 
0 . 1 
2 . 1  
a 
4 . 8  
a 
1 . 9  
a 
8 . 7  
44 . 2  
13 . 4  
a 
0 . 21 
0 . 34 
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Table 1 1. Plasma Carnitine and Triglyceride Levels1 Before and 24 
Hours After the Initiation of Full Strength Breastmilk. 
Parameter Group n Pre-Breastmilk Post-Breastmilk 
NEC
2 I 0 
II 3 14. 2 ± 1. 5 
III 5 20. 1 ± 2. 0 
ASAC
3 I 0 
II 3 3. 5 ± 0. 8 
III 5 6.4 ± 1. 1 
A!.AC
4 I 0 
II 3 0. 8 ± 0. 2 
III 5 1. 1 ± 0. 2 
TC
5 I 0 
II 3 18. 5 ± 1. 1 
III 5 27. 5 ± 3. 0 
TG
6 I 0 
II 3 43 .6 ± 13.4  
III .5 80. 5 ± 22. 7 
Fat 
7 
I 0 
Intake II 3 2. 03 ± 1. 2 1 
III 5 2. 76 ± 0.69 
1 
2 
Values are the means ±  SEM 
3 Non-esterified carnitine (nmol/ml) 
4 Acid-soluble acylcarrµtine (nmol/ml) 
5 Acid-insoluble acylcarnitine ( nmol/ml) 
6 
Total carnitine (nmol/ml) 
7 Triglyceride (ng/dl) Fat intake ( g/k.g/day) 
23. 8 
24. 2 
6. 7  
7. 9 
1. 3 
1 . 5  
31. 8 
33. 7 
80. 0 
94. 8 
3. 99 
4 . 43 
a pre-breastmilk and post-breastmilk values are different 
at p<0. 05 level 
± 1. 6 a 
± 3. 2 
± 1. 6 
± 1. 4 
± 0. 1 
± 0 . 1 
± 1. 8 a 
± 4. 5 
a 
± 33. 2 
± 12 . 4 
± 0. 30 
± 0. 19 
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The NEC :ASAC ratio was virtually unchanged in both groups (Table A-5). 
The increase in TG levels paralleled the increase of fat intake, but 
the changes were were not significantly different from pre-breastmilk 
levels in either group. 
E. Plasma Garnitine Changes With Carnitine Intake 
The relationship between plasma· carnitine levels and dietary 
carnitine intake is presented in Table 12 and Figures 7-10. Both 
carnitine intake reported in µmol/kg/day and in total µmol/day were 
correlated with an increase in the plasma TC, NEC, and ASAC levels. 
However in all groups, the plasma NEC and CNE levels were slightly 
better correlated with carnitine intake when the intake was based on 
µmol/day rather than µmol/kg/day. The difference between the two 
expressions (umol/day or umol/kg/day) was highest in the smallest 
infants (Group I), follCMed by Group II, while the difference had almost 
disappeared in Group III. The plasma ASAC and AIAC were not 
consistently better correlated with carnitine intake expressed either in 
µmol/day or JJJOOl/kg/day. All groups responded to an increased intake of 
dietary carnitine with an increase of plasma TC, NEC, and ASAC. The 
slope of the regression line of TC, NEC, and ASAC was higher in Group I 
infants, however, this group also had the lowest carnitne levels prior 
to carnitine intake. ,Unlike the other groups, infants in Group I showed 
an increase of AIAC with carnitine intake. Between the infants of 
Groups II and III, both showed similar increases in plasma TC, NEC, and 
ASAC levels for any given carnitine intake. 
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Table 12 . Correlations Between Plasma Garnitine Concentrations and 
Daily carnitine Intake . 
Parameter Group r p 
Carnitine Intake (µmol/kg/day) 
TC I 0 . 779 1 . 06E-06 
II 0 . 791 2 . 09E-14 
III 0 . 707 < 1 . 00E-15 
NEC I 0 . 735 8 . 19E-06 
II 0 . 808 2 . 22E-05 
III 0 . 696 3 . 69E.;..07 
ASAC I 0 . 752 3 . 86E-06 
II 0 . 384 2 . 03E-03 
III 0 . 575 6 . 84E-08 
AIAC I 0 . 515 5 . 08E-03 
II -0 . 422 6 . 34E-04 
III -0 . 197' 4 . 20E-02 
Garnitine Intake (µmol/day) 
TC I 0 . 882 5 . 83E-10 
II 0 . 841 <1 . 00E-15 
III 0 . 721  <1 . 00E-15 
NEC I 0 . 851 9 . 72E-09 
II 0 . 882 <1 . 00E-15 
III 0 . 715 <1 . 00E-15 
ASAC I 0 . 787 6 . 78E-07 
II 0 . 317 1 . 20E-02 
III 0 . 567 4 . 39E-08 
AIAC I 0 . 582 1 . 16E-03 
II  -0 . 453 2 . 15E-04 
III -0 . 167 8 . 50E-02 
Variables defined in text . 
Y=dependent variable (plasma carnitine) 
X=independent variable (carnitine intake) 
_ Regression Line 
y = 0 . 859*X + 8 . 913 
y = 0 . 886*X + 18 . 238 
y = 0 . 857*X + 17 . 928 
y = 0 . 656*X + 7 . 247 
Y · = 0 . 805*X + 11 . 825 
y = 0 . 696*X + 12 . 034 
y = 0 . 189*X + 1 . 405 
y = 0 . 093*X + 5 . 438 
y = 0 . 170*X + 4 . 643 
y = 0 . 152*X + 0 . 210 
y = -0 . 013*X + 0 . 978 
y = -0 . 009*X + 1 . 252 
y = 0 . 596*X + 4 . 410 
y = 0 . 431*X + 19 . 446 
y = 0 . 436*X + 18 . 311 
y = 0 . 465*X + 3 . 335 
y = 0 . 402*X + 12 . 528 
y = 0 . 356*X + 12 . 280 
y = 0 . 121*X + 0 . 889 
y = 0 . 035*X + 5 . 956 
y = 0 . 084*X + 4 . 808 
y = O . Oll*X + 0 . 130 
y = -0 . 006*X + 0 . 963 
y = -0 . 004*X + 1 . 226 
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F .  Relationship of Plasma Carnitine and Lipids 
1. Relationship of Plasma Carnitine and Triglyceride 
The correlations between· carnitine and TG levels of infants in 
Groups I-III are presented in Table 13. Th.ere were no significant 
correlations in Group I between any of the plasma carnitines and TG 
levels. In ooth Groups II and III , there were significant positive 
correlations between triglyceride level and the levels of NEC (r=0.211 , 
p<0. 01 and r=0. 337 , p<0. 0001) , ASAC (r=0. 308 , p<0. 001 and r=0.409, 
p<0. 0001), and TC (r=0. 255 , p<0. 01 and r=0. 370 , p<0. 0001) for Groups II 
and III, respectively. The mean NEC:ASAC ratio ·was not significantly 
correlated with triglyceride level in any group (Table A-6) , and there 
were no significant correlations between AIAC and triglyceride levels 
(Table A-7) in any group. 
2. Relationship of Plasma Carnitine and Non-esterified Fatty Acids 
Non-esterified fatty acids were only measured on a limited number 
(n=44) of plasma samples of infants fran the JOOSt premature infants 
(Group I ,  n=144 total plasma samples). Fran these limited data , a · 
p::,sitive correlation was found between plasma TC and NEFA levels 
(r=0. 381 ,  p<0. 05) as shown in Figure 11 and between ASAC and NEFA 
levels (r=0. 344 , p<0. 025) as shown in Figure 12. 
G. Relationship of Short-cha.in Acylcarnitines and Fat Intake 
The correlations between short-cha.in acylcarnitiries (ASAC) and fat 
intake are presented in Table 14. There was a positive correlation 
between fat intake and ASAC in Groups II and III. The correlation 
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Table 13. Correlation Between Plasma Garnitine and Triglyceride 
Concentrations of Individual Infants by Group 
Parameter Group r p 
NEC I -0.098 NS 
II 0.211 <0.01 
III 0.337 <0.0001 
ASAC I -0.034 NS 
II 0.308 <0.001 
III 0.409 <0.0001 
AIAC I 0.004 NS 
II -0.101 NS 
III -0.127 NS 
TC I -0.084 NS 
II 0.225 <0.01 
III 0.370 <0.0001 
Variables defined in text. 
Table 14. Correlation Between Plasma Acid-Soluble Acylcarnitine 
Concentration and Fat Intake. 
Group 
I 
II 
III 
r 
-0.152 
0.400 
0.614 
Variables defined in text. 
p 
NS 
<0.0001 
<0.0001 
Regression Line 
Y = 0.546*X + 4.127 
Y = 0.809*x + 4.230 
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coefficients were r=0.400 (p<0.0001), and r=0.614 (p<0.0001) for Groups 
II and III respectively. There was no significant correlation between 
ASAC and fat intake in Group I (r=-0.152, p>0.05). 
H. Plasma Lipids Related t.o Fat Intake 
1. Plasma Triglyceride Related to Fat Intake 
The correlation between plasma triglyceride and fat intake is 
presented in Table 15. The plasma triglyceride concentration was not 
correlated to fat intake (g/kg/day) in Group I. However, there was a 
significant positive correlation between triglyceride and fat intake in 
Groups II and III (r=0.539, p<0.001 ; and r=0.634, p<0.0001, 
respectively). 
2 .  Plasma Non-esterified Fatty Acids Related to Fat Intake 
As mentioned above, NEFA were determined on a limited sample of 
Group I infant plasma. Of these, no correlation was found between the 
plasma NEFA level and fat intake (r=-0.086 , p=0.581). 
I. Plasma Triglyceride Related to calorie Intake 
The correlations between plasma TG level and calorie intake 
(kcal/kg/day) are presented in Figure 13. The TG level demonstrated a 
significantly positive correlation with calorie intake. The correl­
ation was highest in Group III (r=0.60, p<0.00001), followed by 
Group II (r=0.473, p<0.0001), and Group I (r=0.311, p<0.001). 
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Table - 15. Correlation Between Plasma Triglyceride Concentration 
and Fat Intake . 
Group 
I 
II 
III 
r 
0 . 194 
0 . 539 
0 . 634 
Variables defined in text. 
p 
NS 
<0 . 001 
<0 . 00001 
Regression Line 
Y = 9 . 816*X + 41 . 512  
Y = 12. 754 *X + 38 . 289 
Group I 
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CHAPTER V 
DISCUSSION 
Since the concentration of plasma carnitine in infants is 
dependent upon a dietary source of carnitine, rather than endogenous 
biosynthesis, it is conceivable that infants who receive a 
carnitine-free diet may have an altered lipid metabolism. No study 
has been done with rmlltiple subjects for an extended period of time in 
which the carnitine and lipid status of infants have been monitored 
during various nutritional interventions . To acheive the objective of 
the study, the following paramenters were investigated: (1 ) birth 
(baseline) concentrations of carnitine in the plasma of the infant, 
umbilical cord, and 100ther at various gestational stages; (2 ) plasma 
carnitine levels fo11CMing various infant feedings ; and, ( 3 )  changes 
in plasma carnitine in relation to the changes in the plasma lipid 
concentrations. 
The infants born at <1510 g (Groups I and II ) had a higher plasma 
carnitine level than either the older premature or the term infants at 
birth which is in agreement with other studies (57 ) . 'The carnitine 
levels in infants were higher than either the maternal or umbilical 
cord plasma levels at birth (Figure 1 and Table 3, pp.  39-40 ) .  In 
general, the plasma carnitine levels in infants decreased with 
advancing gestational age after birth, which is in concert with the 
observations of Shenai and Borum (71 ) . However, the 24 . 5  to 31 weeks 
infants exhibited a sharp rise in carnitine which "WaS positively 
correlated with advancing gestational age during this period. Infants 
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of 31.5 to 34 weeks gestation age showed a sharp decline in plasma 
carintine during this period of developnent. The infants of 
gestational age >34 weeks maintained the plasma levels of NEC and TC 
at about 15 and 20 runol/ml, respectively (Figures 2 and 3, pp . 44-45 ).  
These data suggest that the infant acquired carnitine from the 
maternal blood supply which resulted in accumulation of carnitine in 
the plasma pool of the infant during the weeks 24-31 of gestation. 
The plasma pool appeared to decrease during weeks 31-35 of gestation 
which may have been due to transfer of plasma carnitine into fetal 
tissues. It has been suggested that carnitine receptors become active 
with advancing stages of gestation (47 , 71). This suggestion is based 
upon the presence of , (1) a cardiac carnitine binding protein µi 
ventricular homogenates of humans (89) and in the isolated rat 
myocardium (90), and (2) active transp::>rt mechanisms described in 
human skeletal muscle (91) and liver (92) whose maturation time in 
fetal developnent is not known. 
Levels of NEC and TC were decreased in all infants 2 days after 
birth unless they were provided with a source of dietary carnitine. 
HCMever, on day O and day 1 ,  there were marked differences in the 
percent changes of carnitine levels between groups. In Group I, the 
levels of TC and ASAC increased, while at the same time NEC was 
decreased compared with birth values. This may reflect release of 
free carnitine from muscle with subsequent transport to hepatic 
tissues, an effect mediated by an increased level of glucagon 
following birth (93). In addition, the high levels of plasma TC may 
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be due to decreased renal excretion of carnitine since premature 
infant kidneys are not fully functional. 
During this same period {days O and 1 ) ,  Groups II and III showed 
a decrease in both NEC and TC. Group II had a greater decrease in NEC 
and TC than Group III. A possible explanation may be that the renal 
tubular threshold was exceeded, or exceeded to a higher degree in 
Group II due to their higher plasma levels of carnitine. 'The renal 
threshold of carnitine has not been determined in infants. In adults, 
the renal plasma threshold for carnitine excretion was 46. 71 and 51 . 74 
nmol/ml for NEC and TC, respectively { 94 ) .  It is conceiveable that 
infants may have a lower renal threshold for carnitine when compared 
to adults. 'Therefore, as opposed to Group I infants who were unable 
to excrete carnitine, the older infants in Groups II and III may have 
excreted carnitine based on their plasma carnitine level. Since Group 
II had a much higher plasma carnitine that Group III at birth, a 
higher renal excretion may have accounted for their marked decline in 
plasma carnitine after the maternal-placental supply of carilitine no 
longer existed. 
Beg�rmiDJ at day 2, some infants in Group III began to receive a 
carnitine-containing formula, and on day 4, some of the Group II 
infants also began to receive a carnitine-containing formula . After 
this period of the study, the groups could not be meaningfully 
compared with one another in tenilS of absolute mean values of 
carnitine with time (age ) ,  but rather only group trends could be 
observed due to the different f�ing regimes within and between each 
group. 
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The NEC:ASAC ratio remained meaningful since this ratio reflects 
a metabolic state , whereas the absolute values of each tend to reflect 
intake (or lack of intake) of dietary carnitine. A decrease in this 
ratio is correlated with the ability of the infant to oxidize NEFA and 
to undergo ketogenesis for the subsequent release of metabolic energy 
(23). Since the NEC:ASAC ratio decreased in all groups during the 
post-partum period, it appeared that they were able to oxidize lipid 
to some degree. HCMeVer the absolute values of the ketone bodies and 
NEFA will be needed in future studies to qualify and quantify the 
significance of the NEC:ASAC ratio. Yeh et al. (76) found that 
premature infants were only able to attain 40-45% of the ketone body 
levels seen in term infants when NEFA were equally available. 
The NEC:ASAC ratio did not increase to the birth values until the 
calorie intake was approximately 100-110 kcal/kg/day. Tilis may have · 
indicated that the infant depends on endogenous and exogenous fat as 
an energy source until reaching the stated energy intake. Once a 
higher calorie intake is achieved there would be little need for NEFA 
mobilization and ketogensis to support the energy needs of the infant. 
The AIAC levels increased in all infants after birth (Figure 5 ,  
p. 46). Since there is a high glucagon to insulin ratio durng the 
first day after birth (93) , the theory of McGarry et al. (93) may 
eJ<plain the increased, AIAC level. Muscle carnitine may be transported 
to the liver to stimulate carnitine palmitoytransferase (CPT) activity 
with a subsequent increase in long-chain acylcarnitine level. This 
�d be reflected by an increase level of AIAC in the plasma. In 
other studies, the group of McGarry and others (95 , 96), proposed that 
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increased glucagon (an increased glucagon to insulin ratio) not only 
stimulates the concentration of carnitine in the liver , but a low 
hepatic carnitine level may stimulate glucagon levels in the body to 
overcome a lack of carnitine in the liver. The level of hepatic 
carnitine has been found to be lower in the neonate than in the adult , 
however, there was no difference between premature and term infants 
( 71 ) . 
The theory of McGarry and CO-N:>rkers may also explain why Group 
I exhibited the highest levels of ASAC and the lowest ratio of 
NEC :ASAC during the first week of life . Since Group I maintained peak 
AIAC for a longer period of time than any other group, this may 
reflect a continued stimulation of hepatic CPT or just a continued 
higher degree of long-chain fatty acid oxidation. This would increase 
the level of acetylcarnitine, the primary short-chain acylcarnitine 
(ASAC) in the plasma. 
Another intent of this study was to observe plasma TG levels when 
the plasma carnitine concentration was depressed. As seen in Table 13 
(p. 68) a depressed plasma carnitine concentration was not correlated 
with an elevated TG level. In Group I, the mean plasma TC level 
decreased to its lowest level of 6.8 nmol/ml while the mean TG level 
was only 69 ng/dl. The highest mean TG seen in this group was 153 
mg/dl on day 105, while the CNE level was 47. 8 nmol/ml. This 
unexpected observation may be attributed to the small amount of 
long-chain TG provided to these infants. Although most infants were 
placed on TPN with simultaneous intravenous fat emulsion , the typical 
lipid dose administered was less than 1-1.5 g/kg/day (calculated from 
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individual infants during the administration of intravenous lipid fat 
emulsion) . The highest isolated dose given to an individual infant in 
Group I was 2. 14 g/k.g/day followed by an isolated dose of 1 . 84 
g/kg/day. The plasma TG which coincided with these fat intakes were 
99 and 86 ng/dl/day, while the plasma TC levels were only 8 . 9  and 7. 5 
nmol/ml and NEFA levels were 0 . 52 and 0. 61 meq/1 for the respective 
plasma sample. One infant in Group I exhibited hypertriglyceridemia 
(TG was 179 ng/dl) while the TC level was 7. 1 nmol/ml and the infant 
had received most of the dietary fat as MCT (Portagen, 88% MCT) . The 
average period of time that intravenous fat was the sole source of fat 
intake in Group I was 6 days, at which time Portagen feediD:Js were 
usually begun. nus might account for why these infants did not 
,receive a high dose of intravenous fat. 
Therefore, most infants in Group I had a relatively small dose of 
long-chain TG when plasma carnitine was at the lowest levels. This 
may explain why there was not an extreme elevation of TG in Group I 
infants during this period . However these infants did not receive a 
100 kcal/kg/day energy intake until day 56, and may have benefitted 
from a higher intake of fat . 
The changes of plasma carnitine and triglyceride levels were 
positively correlated in both Groups II and III (Table 13 , p. 68) . 
Infants in Group II, like Group I, were all placed on TPN during 
hospitalization. All but 2 infants were given simultaneous 
intravenous lipid enru.lsion . Once again , during the period of time 
when the plasma carnitine concentrations were depressed and/or still 
decreasing (during TPN, fat emulsion, and Portagen feedings) ,  only a 
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small dose of long-chain TG was given to these infants. The dose of 
intravenpus lipid administered was typically less than 1. 0 g/kg/day 
and the highest isolated d� administered was 1. 46 g/kg/day, followed 
by a dose of 1. 35 g/kg/day. The corresponding TG levels were 37 and 
79 ng/dl and the TC levels 16. 4 and 12. 6 nmol/ml. As 
carnitine-containing feedings began ( Enfamil-Premature Formula , 
Enfamil-20, and breastmilk), there were significant increases of TC 
and NEC. Although not always significant, there was a trend that TG 
also increased during this time while accompanied by an increased 
intake of long-chain TG (Tables 9-11 and Figures A-4-6). 
Group III infants also showed a positive correlation between 
plasma carnitine and triglyceride levels (Table 13, p. 68). While 9 
of the 16 infants were placed on TPN, only 3 infants :r;eceived 
simultaneous intravenous fat emulsion. The highest isolated fat dose 
during fat emulsion administration was only 0. 83 g/kg/day. t-t:>st 
infants in Group III began receiving carnitine-containing formula 
which also contained a high percentage of long-chain TG ( Enfamil-20 or 
breastmilk) soon after initiation of TPN. Therefore the levels of TC 
and NEC increased in Group III infants within the first- week of life 
( Figure 4, p. 46). With the intake of Enfamil-20 and breastmilk, 
there was also a trend for TG to increase ( Tables 10 and 11, pp. 
59-60), which would be a reflection of their high content of 
long-chain TG ( Table A-1). 
No group showed a significantly negative relationship between 
plasma carni tine and TG during the study ( Table 13, p. 68) . However , 
there was a trend that infants of Group I showed a slight negative 
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correlation between the two parameters (r=-0.098 and 0 . 084 for NEC and 
CNE with TG, res:pectively) . This was in accordance with the 
observations of DeLeeuw et al. (97) who found that prematurity was one 
of the most important factors leading to hypertriglyceridemia in 
newborns. It may be significant that only Group I had a negative 
correlation between plasma carnitine and TG. This might indicate that 
these infants had an inadequate reserve of carnitine with subsequent 
accumulation of TG in the plasma. 
Another objective of this study was to observe the changes in 
plasma carnitines and TG with various nutritional interventions. The 
interventions included were 'l'PN, fat emulsion, Portagen , Enfamil­
Premature Formula, Enfamil-20, and breastmilk. For reference, the 
carnitine and fat content of each of these are presented in Table 5 
(p. 51) and Table A-1. 
During the first 24 hours of TPN administration all infants 
exhibited a decrease TC, NEC, and AIAC. When compared to pre-TPN 
values, only Groups II and III experienced a significant decrease in 
plasma NEC and TCE at 24 hours after the initiation of TPN. Infants 
in Group I had the largest mean decrease in NEC and CNE, but due to a 
large variance within the group these changes were not statistically 
significant . 
As the duration of TPN feedings advanced, Groups I and II 
continued to show a decline of plasma carnitines, while only a small 
depression of carnitine was maintained in Group III . In Group III, 
the levels of NEC and TC were increased over the 24 hour post-TPN 
level, but were still below the pre-TPN level . These increases are 
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attributed to 2 infants of this group who had a small increase of NEC 
and TC during TPN administration and before they had received dietary 
carnitine . This finding may iooicate that the older infants were able 
to synthesize carnitine. However , both of these infants began 
receiving phototherapy treatments for hyperbilirubinemia during 24 
hour post-TPN and the discontinuation of TPN. Phototherapy has been 
shown to result in lipid peraxidation with subsequent red blood cell 
hemolysis in infants (98). Borum (57) proposed that up to 70% of the 
blood carnitine is present in the red cells. It is conceivable that 
the observed increases of carnitine may reflect a medical treatment , 
rather than infant carnitine synthesis. 
The decrease of plasma carnitines in infants on TPN is in 
accordance with other studies (73 , 77). This is in contrast to adults, 
who maintain plasma carnitine levels for at least 20 days during 
administration of TPN (99). The plasma TG levels remained constant 
except in Group II where a significant decrease was observed at 24 
hour post TPN. There were no significant changes in plasma TG levels 
canpared to pre-TPN levels in any group upon discontinuation of TPN. 
In case the infants were receiving a carnitine-containing feeding 
along with TPN, the TG value used in calculations was the one obtained 
prior to coadministration of the carnitine-containing formula. 
The administration of intravenous fat emulsion did not result in 
a significant change of plasma carnitine in any group (Table 7 ,  p. 54 
and Figure A-2). However there were slightly increased levels of NEC 
and TC in all groups 24 hours after initiation of lipid emulsion even 
though this preparation does not contain carnitine. This might 
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reflect a decreased urinary excretion of carnitine, which was observed: 
by Konig et al (100) , in adults after administration of intravenous 
lipid emulsion. Unlike the observations made in the infants of this 
study, Konig found 16% lqwer plasma carnitine levels after intravenous 
lipid emulsion. 
The admistration of intravenous fat resulted in a decreased 
NEC:ASAC ratio in Groups I and III. This was similar to the results 
in rat. studies were provision of a high fat diet caused an increase of 
acylcarnitine , but not of NEC. This indicated that these infants were 
probably able to oxidize either the lipid emulsion or endogenous lipid 
with subsequent prcxiuction of short-chain acylcarnitines. 
There was a decrease in plasma TC and NEC levels during Portagen 
feedings (Table 8, p. 56 and Figure A-3). This was an eJ<pected result 
since Portagen does not contain a significant amount of carnitine. 
These decreases were significant in Groups I and II , but not in Group 
III. Group I had a larger decrease of TC and NEC than Group II. 
However, there was also a longer time interval between the pre- and 
post-Portagen values due to the longer period of time needed to attain 
a full strength formula rate in the Group I infants, (19 days in 
Group I versus 9 days in Group II) . There were no statistically 
significant changes seen in triglyceride when canpared to pre-Portagen 
values in any group. ,Group I infants had a decrease in plasma TG 
despite a higher intake of dietazy fat (4.16 g/kg/day), while Group 
III had a large increase of plasma TG while they received only 1.08 
g/kg/day of dietary fat. 
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Infants placed on Enfamil-Premature Formula sh.owed a substantial 
increase in the mean TC and NEC levels (Table 9, p. 57 and Figure 
A-4) . However, only Group II had a statistically significant increase 
in these parameters. In Group I, the increase of NEC and TC levels 
were not statistically different frc:m pre-Enfamil-PF values due to the 
small number of infants who received Enfamil-PF. Also, 1 of the 3 
infants in Group I shc:Med only a slight increase in TC and NEC (pre : 
6. 7 runol/ml and post: 9. 3 runol/ml) whereas the other 2 infants showed 
a marked increase in both of these parameters (pre: 7.6 and 8.5 
ruool/ml ; and post: 27. 0 and 33. 6 nmol/ml) Reasons for this infant 
not showing a rapid increase in plasma carnitine as did the others may 
be that there was a decreased gastrointestinal absorption, or an 
increased renal excretion, or an increased tissue accretion of 
carnitine during this time. 
Plasma TG increased in each group during Enfamil-PF 
administration (Table 9, p. 57). There was a significant increase of 
plasma TG only in Group II. These infants also had the highest mean 
increase of fat intake between pre- and post-Enfamil-PF values. This 
might explain why only Group II had an increase in TG. Although fat 
intake was relatively high in Groups I and III (5.23 and 4 . 71 
g/kg/day, respectively), there was no hypertriglyceridemia (TG>160 
ng/dl) observed at 24,hours after receiving full strength Enfamil-PF. 
However, Enfamil-PF contains a relatively high concentration of medium 
chain triglycerides (43%) which are known to reduce the incidence of 
hypertriglyceridemia. Enfamil-PF also contains a relatively high 
calcium concentration. A high calcil.Dil intake has been shown to 
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decrease the fat absorption coefficient (101) which may prevent an 
elevation of plasma TG in infants on this fonnu.la. 
During Enfamil-20 feedings, there were significant increases of 
TC and NEC in all groups (Table 10, p. 59 ·an.a Figure A-5). T"nis is 
reflected in the changes of plasma carnitine with the increased intake 
of dietary carnitine (Table 12, p. 62 and Figures 7-10, pp. 63-66). 
Plasma TG increased in all groups, but only significantly in Group 
III, perhaps because Group III infants had the largest increase in 
fat intake. This is evident from the high correlation ( r--0. 634) 
between plasma ·TG level and fat intake in Group III (Table 15, p. 71). 
Breastmilk feedinJS also resulted in an increase in the levels of 
all fractions of plasma carnitine and in plasma TG (Table 14, p. 68). 
Although warshaw and CUrry (102) fourd that tenn infants which 
received breastmilk had higher plasma NEC levels than infants on 
cotmnercial infant formula, and that this is supposedly due to a higher 
bioavailability of carnitine in breastmilk, this did not appear to 
occur in this study of premature infants. However, most infants in 
this study were not given breastmilk prior to other 
carnitine-containing formula, which would not allow a true comparison 
between the rise of plasma carnitine between the � types of 
feedings. 
The results of carnitine determination of infant formula (Table 
5, p. 51) confirmed once again that infant formula based on soybean 
protein are deficient in carnitine and those formula that are 
milk-based have a high concentration of preformed carnitine (44). 
However, the carnitine levels of the two milk-based formula were 
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markedly different from one another. This might be explained by the 
addition of demineralized whey to Enfamil-Premature formula, which 
contained almost double the amount of carnitine found in Enfamil-20. 
Ohtani (43) suggested that formulas with a high whey to casein ratio 
have a higher concentration of carnitine. However, both Enfamil-PF 
and Enfamil-20 contain a 60:40 ratio of whey:casein proteins. 
Therefore, the difference in carnitine concentration between the tw:> 
formulas may be due to the different protein contents (Enfamil-PF, 
2.4 g/dl ; Enfamil-20, 1.5 g/dl), or to their concentration, rather 
than to the addition of whey. 
Thus, it appeared that plasma carnitine decreased in all groups 
receiving a carintine-free diet but increased once dietary carnitine 
was introduced into the infant diet. The level of plasma carnitine 
corresponding to a given dietary carnitine intake (µmol/day) was 
similar between groups. As sham in Table 12 (p. 62), the rate of 
plasma carnitine increase was highest in . Group I (slope-0 . 596) 
canpared to Groups II and III where the slopes were similar (0. 431 and 
0. 436 respectively). This may be explained by the lower plasma 
concentrations of carnitine attained in Group I before initiation of a 
carnitine-containing diet. When carnitine intake was expressed as 
µmol/kg/day, the increase of plasma carnitine compared with carnitine 
intake was similar between all groups. 
The plasma NEFA levels were determined on 44 samples from infants 
in Group I. The NEFA level was positively correlated with the plasma 
level of TC ( Figure 11, p. 69) . This is not in accordance with most 
studies (24, 75, 76). However, these NEFA values included birth NEFA 
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levels which are known to be elevated due to the endocrine response in 
the post-partum period. The NEFA were determined from plasma samples 
obtained during administration of intravenous fat emulsion, Portagen 
feedings, and in some infants, during theophylline and dopamine 
therapy. Therefore, the NEFA levels reflect either the relatively 
small doses of fat emulsion, the administration of a high 
M:T-containing formula, or a drug therapy, each of which may have 
influenced the plasma NEFA level. Another factor that must be 
considered is the length of time the plasma samples were stored before 
the .NEFA levels were determined. M:>st were kept for several months at 
-20 °. Forbes reported that the serum NEFA concentration may increase 
up to 63% within 24 hours when stored at ...:15° (103), while Gordon 
found plasma NEFA may be stable for several weeks when kept at -20° 
(104). Since the primary focus of this study was to observe plasma 
carnitine changes during infancy, the carnitine determination was done 
in advance of either TG or NEFA to insure an adequate plasma volume 
for the carnitine assay. The NEFA determinations were made only as a 
probing observation as a guide for future studies and will not be 
considered in the final sumnary of this study. 
Based on this study and the research of others, it appears that 
premature infants have deficient plasma carnitine levels which may 
indicate a tissue carnitine deficiency as well. Since this population 
is heavily dependent on dietary carnitine which may not be available 
to most of these infants, it is necessary to determine (1) the 
relationship between the plasma and tissue pools of carnitine during 
infancy, (2) the ability of the premature neonate to utilize NEFA as 
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evidenced by the plasma ketone and NEFA levels, and as related to the 
carnitine pools, (3) the optimal intravenous lipid doses needed for 
the high energy needs of the premature infant without causing lipid 
intolerance as related to the carnitine pools, and (4) the effect of 
carnitine supplementation (both oral and intravenous) on the plasma 
lipid profile on the premature infant. 
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CHAPTER VI 
Th.is study was designed to detennine the plasma carnitine status 
of premature infants from birth until discharge from hospital care. 
Plasma carnitine levels were detennined in 3 groups (based on 
birthweight) of premature infants at birth, in maternal and in 
umbilical cord plasma to assess the relationships between the three at 
various stages of prematurity. The groups were: Group I <1000 g, 
Group II 1001-1510 g, Group III 1511-2500 g, and Group IV (reference 
group) consisted of full term infants. After birth, plasma carnitine 
levels were determined daily for the first week (except day 6) and 
then weekly to monitor plasma carnitine changes with advancing age. 
Plasma carnitine was also determined before and after various 
nutritional interventions to observe the effects of both 
carnitine-free and carnitine-containing diets. carnitine levels were 
related to plasma lipid levels to determine whether a significant 
correlation exists between these two variables. 
The results showed that plasma carnitine levels are higher in 
the premature infants with a birthweight <1510 g than in premature 
infants with a birthweight of 1511-2500 g or full tenn infants. The 
level of plasma carnitine in the infant was higher than either 
maternal or umbilical cord plasma. 
After birth, the infants in this study with only two exceptions 
required an exogenous source of carnitine for maintenance of plasma 
carnitine. � infants in the highest birthweight group showed a 
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slight rise in non-esterified and total carnitine while receiving 
total parenteral nutrition. Since total parenteral nutrition does not 
contain preformed carnitine, the increase of plasma carnitine may have 
reflected endogenous synthesis of carnitine. This. increase might li.ave 
been due to carnitine release from red blocxi cells , since both of 
these infants rec�ived phototherapy during the time when plasma 
carnitine increased. This has not been re:ported in the literature and 
would warrant further research. 
The results furthermore showed that infants given a 
carnitine-containing formula responded with an increase in plasma 
carnitine. There was a positive correlation between TC and TG for 
Groups II and III (r=0. 308 arxl r=0 . 225, p<0.01). However , there was a 
small, but insignificant, negative correlation between plasma 
carnitine and triglyceride in Group I (r=-0 . 098). There were no 
episodes of hypertriglyceridemia when total carnitine was less than 26 
nmol/ml, even though some of the infants had a decrease in carnitine 
to a level belc:Nl 10 IlJJK>l/ml while on a carnitine-free diet. It must 
be noted that only small amounts of fat in the form of long-chain 
fatty acids were given during the pericxi when plasma carnitine levels 
were the lowest. 
Thus it appears that plasma carnitine was dependent u:pon an 
exogenous source of carnitine in the premature infant. But a 
depressed plasma carnitine was not necessarily associated with hyper­
triglyceridemia at the level of fat intake provided in this study. 
Further research is needed to determine if plasma carnitine and tissue 
carnitine levels are related, and if so, would these also be related 
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to an elevation of the NEFA: albumin molar ratio and to inability of 
the infant to produce ketone bodies. If fat intolerance was found to 
be correlated with a depressed carnitine concentration , there may 
exist a need for carnitine supplementation in this population . 
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Table A-1. Fat Content of Infant Formulas
1 
and Liposyn� 
Fat 
Content Portagen Enfamil-PF 
Total Fat 3.2 4 . 1  
( g/dil) 
calories 40 44 
as fat (%) 
Source of Fat ( % )  
Corn Oil 12 40 
Safflower Oil 0 0 
Soybean Oil4 0 0 Coconut Oil 0 20 
MCT Oil 88 40 
� Meade-Johnson product information 
3 
Ross-Abbott product information 
Enfamil-20 Liposyn 
3 . 8  10 
50 98 
0 0 
0 100 
45 0 
55 0 
0 0 
Breastmilk3 
3 . 76 
55 
NA 
NA 
NA 
NA 
<4 
4 Reference 105 Coconut Oil contains 59% medium-chain fatty acids (sC : 12 )  (Ref. 106) 
103 
Table A-2 . Plasma carnitine Levels (nmol/ml)
1
'
2 
at Birth3 for 
Maternal, Unbilical Cord, and Infant Plasma (Paired )" .  
Group n Maternal 
Total Garnitine 
I 2 22 . 5  ± 2 . 5  a, f 
II 3 25 . 1  ± 9 . 5  a, f 
III 8 16 . 4  ± 1 .  7 a, g 
IV 10 16 . 4  ± 1 . 0  
a, g 
Non-Esterified Garnitine 
I 2 15 . 9  ± 3 . 9  a, f 
II 3 20 . 0  ± 8 . 2  a, f 
III 8 10 . 7  ± 0 . 7  a, g 
IV 10 12 . 2  ± 0 . 8  a, g 
Acid-Soluble Acylcarnitine 
I 2 4 . 8  ± 1 .  l a, f 
II 3 4 . 1  ± 1 . 5  a, f 
III 8 4 . 7  ± 1 .  2 a, f 
IV 10 3 . 6 ± 0 . 6  a , f 
Acid-Insoluble Acylcarnitine 
I 2 
II 3 
III 8 
IV 10 
1.8 
0 . 9  
1.0 
0 . 8  
± 
± 
± 
± 
o 2 
a, f 
0 • 1 ab, f 
0
· 3 ab, f 
0 : 1 b ,  f 
Cord Infant 
32 . 3  ± 17 . 6  a, f 26 . 3  ± 4 . 7  a, f 
19 . 5  ± 1 . 8  a, f 31 . 4  ± 9.0 a, f 
22 . 1  ± 2.7 a, fg 24 . 6  ± 2.6 a, f 
20.3 ± 1 .  l a, f 21 . 0  ± 1. 4 a, f 
14 . 2  ± 13 . 1  a, f 18 . 4  ± 3.7 a, f 
13.5 ± 0 . 4  a, f 23 . 7  ± 5.1 a, f 
15 . 8  ± 1 .  5 a, f 18 . 9  ± 2 O a, f 
15 . 0  ± 0.7 a, f 15.2 ± 1 : 1 b, f 
9 . 3  ± 4 . 4  a, f 6.8 ± 0 . 6  a, f 
4 . 8  ± 1 .  7 a, f 6.9 ± 3 . 6  a, f 
5.6 ± 1 .  l a, f 5.0 ± 1 .  0 a, f 
4 . 4 ± 1 . 0  a, f 5 . 2 ± 0 . 7  a, f 
1 . 4  ± 0 . 1 a , f 1 . 1 ± 0 . 4  a, f 
1 . 2  ± 0 . 3  a, f 0 . 8  ± 0.2 a, f 
1 . 0  ± 0 . 2 a, f 0 . 8  ± 0 . 2  a, f 
0 . 8 ± 0.1 a, f 0 . 7  ± 0.1 a, f 
� Values are the group means ± SEM 
Means in a re,,, or column without a common superscript letter are 
3 different ( p<
O . 05) · -
Plasma samples were obtained within 8 hours post-partum 
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Table A-3. Plasma Triglyceride Levels (ng/dl)
1 ' 2 at Birth
3 
for 
Maternal, Umbilical Cord, and Infant Plasma ( Paired). 
Group n Maternal Cord Infant 
I 2 89 ± 7 a, f 63 ± 39 a , f 39 ± 19 a , f 
II 3 192 ± 54 
a, f 
34 ± 13 a, f 34 :t a a , f 
III 8 166 ± 25 a, g 23 ± 4 a, f 24 ± 4 a , f 
IV 10 175 ± 27 a, g 30 ± 5 a , f 26 ± 15 a, f 
; Values are the group means ± SEM 
Means in a row or column without a conmen superscript letter are 
3 
dif ferent (p<0.05) 
Plasma samples were obtained within 8 hours post-partum 
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Table A-4. Ratio of Total carnitine Levels1 for Maternal, Umbilical 
Cord, and Infant Plasma. 
Group Maternal Cord Infant 
I 1 0 . 97 1 . 45 
II 1 0 . 81 1 . 20 
III 1 1 . 38 1 . 61 
IV 1 1 . 23 1 . 28 
1 Values represent the ratio of the mean unpaired total 
carnitine (TC) levels for each group. 
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Table A-5. The NEC : ASAC Ratio Changes with Nutritional Intervention. 
NEC :ASAC Group 
( of group x) I II . III 
Pre-TPN 2 . 39 3. 30 2 . 82 
24 °Post-TPN 2 . 50 2 .63 3 . 73 
Post-TPN 1. 79 2 .44 3. 77 
Pre-IV Fat 2. 90 2 . 53 4 . 58 
Post-IV Fat 2 . 57 5. 07 3 .65 
Pre-Portagen 3. 78 4 . 95 5 . 96 
Post-Portagen 1 . 88 2 .46 3 . 20 
Pre-Enfamil-PF 6. 02 1. 83 NA 
Post-Enfamil-PF 3. 85 4. 09 NA 
Pre-Enfamil-20 1 . 51 2 . 06 3 . 02 
· post-Enfamil-20 4.67 3.61 2 . 28 
Pre-Breastmilk NA 3. 79 . 3 . 14 
Post-Breastmilk NA 3 .69 3 . 06 
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Table A-6. Correlation Between Plasma Triglyceride 
Concentration and the NEC:ASAC Ratio . 
Group 
I 
II 
III 
Variables defined in text 
r 
-0 . 011 
-0. 131 
-0. 149 
p 
0 . 19 
0 . 12 
0 . 062 
Table A-7. Correlation Between Plasma Triglyceride 
and Acid-Insoluble Acylcarnitine Concentrations. 
Group 
I 
II 
III 
Variables defined in text 
r 
0. 004 
-0. 101 
-0 . 127 
p 
NA 
NA 
NA 
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Figure A-2 • Cami tine Fractions by Group Before and 24 Hours After 
Intravenous Lipid Infusion. 
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Figure A-3 . Carni tine Fractions 17:l Group Before and 24 Hours After 
Achievement of Ft.tll Strength Portagen. 
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Figure A-4 . Carnitine Fractions by Group Before and 24 Hours After 
Achievement of Full Strength Enfamil-Premature Formula. 
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Figure A-5 . carnitine Fractions by Groups Before and 24 Hours After 
Achievement of Full Strength Enfamil-20 .  
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Figure A-6 . carnitine Fractions by Group Before and 24 Hours After 
Achievement of Full Strength Breastmilk. 
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